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 Annotation 
Virus-like particles (VLPs) are protein structures formed from one or few types of protein 
capable to self-assemble in complex and highly organised structures. Due to the symmetrical 
fashion and multimeric structure pattern, VLPs can be used in two ways – as perspective carriers 
for exposition of foreign sequences and as a delivery vehicles containing packaged cargo inside 
them. One of the most promising area of VLPs utilization is vaccine development. 
Bacteriophages GA and AP205 are among one of the smallest and simplest viruses, extensively 
used as a study model for molecular biology. Coat protein expressed in bacteria or yeast forms 
VLPs. Another object – hepatitis B virus (HBV) core protein produced as recombinant protein 
also self-assemble into VLPs. 
The aim of the work was to test various virus-like particle usage possibilities, therefore 
different test objects were used. First, West-Nile virus protein E domain III (WNV-DIII) protein 
sequence attachment to AP205 coat protein leaded to mosaic particle formation when expressed 
in E.coli cells. Mosaic particle formation was also achieved when HIV-Tat or WNV-DIII 
protein sequences were genetically attached to phage GA coat protein and expressed in yeast. 
Both WNV envelope protein equipped carriers showed specific immune response. Second, in 
vivo packaging of IL-2 and GFP mRNA into GA coat protein particles synthesized in 
S.cerevisiae was achieved.  The packaging was improved by supplementing MS2 operator 
sequence to mRNA and using GA VLP mutants that mimicks MS2 operator binding site. Third, 
the methodology to obtain empty full-length HBV core VLPs was elaborated and successfully 
used for both bacteria- and yeast-produced particles. Four novel HBV core proteins (HBc-K75, 
HBc-K77, HBc-K79, HBc-K80) with lysine point-mutations on the protruding structure 
elements of particles, reveal perspective for addressing through chemical coupling. We proved, 
that elaborated alkali treatment method is effective for obtaining empty particles for all six cases 
– yeast-source, bacteria-source, as well for four lysine mutants. Fourth, in vitro packaging of 
nucleic acid fragments into alkali-treated empty HBc VLPs was studied. Packaging of DNA 
fragments was achieved through scarification of particles in urea and subsequent 
reconstruction, whereas RNA and short oligodeoxynucleotides were included in VLPs by 
simple mixing. Individual double-stranded DNA fragments of maximum length in range 
between 1289 to 1737 base pairs were found as packaged in equimolar ratio, whereas longer 
DNA fragments / plasmids were embraced by empty particles in large molar excess of them. 
Packaged DNA was protected from DNAse, whereas RNA, despite its capability to bind and 
package into VLPs, after extraction showed strong degradation, possibly explainable with 
ribonuclease activity of empty HBc VLPs. 
Our novel and perspective technologies in field of small RNA phage and HBv core based 
virus-like particles can be used for vaccine development or utilized for generation of delivery 
cargo with abilities te be chemically addressed for specifical targeting and interaction with cells 
of interest. 
 
Keywords: VLP, core, packaging  
 Anotācija 
Vīrusiem līdzīgās daļiņas (VLD) ir proteīnu struktūras, kas veidotas no viena vai vairāku 
veidu proteīniem, kas spējīgi pašsavākties kompleksās un augsti organizētās struktūrās. 
Simetriskās un multimērās struktūras dēļ VLD var tikt izmantotas divos veidos – kā perspektīvi 
svešu sekvenču nesēji un eksponētāji, un kā piegādes vektori ar iepakotu kravu tajos. Viena no 
daudzsološākajām VLD pielietojuma jomām ir vakcīnu izstrāde. Bakteriofāgi GA un AP205 ir 
vieni no mazākajiem un vienkāršākajiem vīrusiem, plaši izmantoti kā modeļobjekts 
molekulārajā bioloģijā. Apvalka proteīnu ekspresējot baktērijās vai raugos, veidojas VLD. Cita 
objekta – hepatīta B vīrusa (HBV) core proteīna gadījumā, tas kā rekombinants proteīns spēj 
pašsavākties vīrusiem-līdzīgās daļiņās. 
Darba mērķis bija pārbaudīt dažādas vīrusiem līdzīgo daļiņu pielietojuma iespējas, tāpēc 
tika izmantoti dažādi testa objekti. Pirmkārt, West-Nīlas vīrusa E proteīna DIII domēna (WNV-
DIII) proteīna sekvences piesaistīšana pie AP205 apvalka proteīna un ekspresija E.coli šūnās 
nodrošināja mozaīkveida daļiņu veidošanos. Mozaīkveida daļiņas veidojās arī ģenētiski 
pievienojot HIV-Tat un WNV-DIII proteīnu sekvences pie GA apvalka proteīna un ekspresējot 
tās raugos. Abi WNV apvalka proteīnu saturošie nesēji parādīja specifisku imūno atbildi. 
Otrkārt, tika novērota IL-2 un GFP mRNS in vivo iepakošana GA apvalka proteīna veidotajās 
VLD, sintezējot tās S.cerevisiae. Iepakošanās tika uzlabota, papildinot mRNS ar MS2 operatora 
sekvenci un izmantojot GA VLD mutantus ar MS2 operatoram līdzīgu operatora saitu. Treškārt, 
metodika tukšu pilna garuma HBV core daļiņu iegūšanai tika izstrādāta un veiksmīgi pielietota 
daļiņām, kas ekspresētas baktērijās un raugos. Četri jauni HBV core proteīni (HBc-K75, HBc-
K77, HBc-K79, HBc-K80) ar lizīna punktveida mutācijām uz daļiņu ārējās virsmas var tikt 
izmantoti perspektīvai adresēšanai, izmantojot ķīmisko piešūšanu. Mēs pārbaudījām, ka 
izstrādātā sārmainās apstrādes metode ir efektīva visu sešu veidu – bakteriālās izcelsmes, rauga 
izcelsmes un četru lizīna mutantu – tukšo daļiņu iegūšanai. Ceturtkārt, tika pētīta nukleīnskābju 
fragmentu in vitro iepakošana ar sārmu apstrādātajās tukšajās HBc VLD. DNS fragmentu 
iepakošanai tika izmantota daļiņu uzirdināšana urīnvielā un tai sekojoša rekonstrukcija, 
savukārt RNS un īsi oligodezoksinukleotīdi tika iekļauti VLD sastāvā tos vienkārši pievienojot. 
Tika parādīts, ka individuālie divpavediena DNS fragmenti ar maksimālo garumu starp 1289 
bp un 1737 bp ir spējīgi iepakoties daļiņās vienādās molārās attiecībās, savukārt garāki DNS 
fragmenti un plazmīdas tika ieskautas ar tukšajām daļiņās to lielā molārā pārākumā. Iepakotās 
DNS bija pasargātas no DNāzes, turpretim RNS gadījumā, neskatoties uz tā spēju piesaistīties 
un iepakoties tukšās VLD, tik novērota spēcīga izekstraģētā materiāla degradācija, ko varētu 
skaidrot ar iespējamu tukšo HBV core VLD ribonukleāžu aktivitāti. 
Mūsu jaunās un pespektīvās tehnoloģijas mazo RNS fāgu un HBV core pētījumu jomā 
var tikt izmantotas vakcīnu izstrādei vai arī pielietotas piegādes vektoru izveidei ar spēju tikt 
ķīmiski adresētām specifiskai mijiedarbībai ar šūnām. 
 
Atslēgvārdi: VLD, core, iepakošana 
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The aim and tasks of research 
The aim of the work was to test various modification and usage possibilities of 
bacteriophage GA and AP205 and hepatitis B virus (HBV) core protein assembled virus-like 
particles (VLPs). 
Therefore following tasks were established: 
 genetical introduction of HIV-Tat and WNV envelope protein sequences into phage GA 
and / or phage AP205 coat protein formed particles; 
 characterization of WNV protein sequence bearing VLPs immunogenicity in mice; 
 approbation and improvement of two-promoter yeast expression system for phage GA coat 
protein expression and particle assembly; 
 in vivo packaging of IL-2 and GFP mRNA into phage GA VLPs; 
 creation of technology for repackaging of full-length HBV core particles and testing this 
system with various nucleic acid based substances; 
 introduction of lysine in the core protein in the outer region of particle’s surface to enlarge 
chemical coupling features of HBV core formed VLPs 
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1. Literature overview 
1.1. Virus-like particles 
Virus-like particles or VLPs are multimeric nano-size particles, formed from self-
assembly competent proteins of viruses of different origin and lacking infectious nucleic 
content. VLPs come from broad spectra of viruses, including them different in shape, genome 
type, infecting species and complexity. Highly complex VLPs are so-called enveloped VLPs 
consist from nucleocapsid that is surrounded with lipid bilayer (comprised from cell 
membrane), containing lipoproteins within outer layer. Simpler are protein-only VLPs, formed 
from structural proteins capable to self-assembly into highly oriented symmetric structures, 
morphologically similar to virus source structures. According shape, non-enveloped particles 
are divided into two groups – either spherical (icosahedral) or filamentous (rod-shaped) ones. 
Development of genetical methods provided not only synthesis of such recombinant structures; 
in many cases VLPs were capable to include foreign sequences – epitopes, addresses and 
markers – without loss of self-assembly. Such amino acid sequences – epitopes – can be used 
not only as a functional motifs (such as DNA/RNA binding sites, receptor/receptor binding 
sequences, etc.), but also as antigenic determinants (for detailed review see (Pumpens and 
Grens, 2002; Roldão et al., 2010; Zeltins, 2013)). VLPs structure forming proteins can be 
synthesized and VLPs can be obtained in various expression systems, specifically, in bacteria 
and yeast cells, baculovirus / insect system, in mammalian cells and also in plant-based systems 
(for review see (Pushko et al., 2013). Despite advanced functions of other expression systems, 
expression in E.coli as a producer leads to good VLPs yields and approved purification 
procedures.  
From a vast majority of virus-like particle candidates, in our work we used recombinant 
self-assembled structures from hepatitis B virus and from one kind of the simplest viruses – 
RNA bacteriophages AP205 and GA. In case of bacteriophage GA and AP205 particles are 
formed from coat protein, in case of Hepatitis B virus the core protein serve as a base of VLPs. 
All those three objects share common property – they are protein-only VLPs. These VLPs are 
highly structured particles mimicking conformation of native viruses, but lacking genome and 
therefore also infectivity. Safety provided by VLPs is main thing of importance when potential 
vaccine candidates are developed. 
To rise the potential of VLPs, foreign sequences from organisms of the different origin 
can be added, generating so called chimeric VLPs. Chimeric particles reveal additional 
functions of the VLPs, main of them are targeted delivery of particles and induction of specific 
immune response. One of the possible usage of the protein-only VLPs is addressing that can be 
done generally in two ways – through chemical coupling or genetic attachment. The chemical 
attachment of foreign sequences is more universal and somehow reliable method, leaving VLPs 
intact. On other hand – genetic attachment of foreign sequences to the VLPs forming protein 
provide clearly defined amount and also spatial orientation of attached amino acid sequence. 
Such a particles can carry more than one type of attached sequence, however different strategy 
of VLPs formation should be used – either multiepitope peptide-loaded VLPs (Ding et al., 2009) 
or mosaic VLPs need to be expressed. Mosaic VLPs are particles, consisting from different 
types of VLP forming protein monomers, and mostly they consist from unmodified structural 
protein and from this protein supplemented with desired sequence. This method is widely used 
when it is not possible to obtain the particles due to the negative impact on VLPs formation, 
caused by genetically added foreign protein sequence. At the same time such approach in 
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process of VLPs modelling allows dosing of the foreign protein in the particle, thereby 
admitting to vary with binding specificity or immune response. Latter one statement can be 
extended by constructing mosaic virus like particles, consisting from more than two different 
proteins. These are so called hybrid VLPs, displaying (at least) two different peptides on a 
single virus-like particle (Tyler et al., 2014). 
Virus like particles can be used in different approaches – as a delivery vessels by 
packaging some useful preps into themselves or as an exposition vectors by containing 
sequences on the outer surface of VLPs possible to interact with specific receptors or elicit 
certain response from cells. These two properties can be unified to obtain packaged particles 
equipped with specific addresses, possible to serve as a cell directed delivery vectors (for review 
see (Garcea and Gissmann, 2004; Pokorski and Steinmetz, 2011)). 
1.1.1. Immunology 
Although targeted delivery is a perspective way for the VLPs to be used, main interest of 
the VLPs could be related with its role as a tools for immunisation. The use of VLPs in the past 
decade in vaccine development has been increased considerably, leading to development of so-
called “nanovaccinology” (Mamo and Poland, 2012). Nano-particles are used in both 
prophylactic and therapeutic approaches, it also includes them either as delivery systems for 
enhanced antigen processing and/or as immunostimulant adjuvant for activation or 
enhancement of the immunity. From immune system point of view VLPs are the right-sized 
particles (between 10nm to 100nm in diameter) to be taken up in lymph nodes to elicit strong 
immune response even without adjuvants. Due to the highly symmetrical structure and 
possibility to add various immunological epitopes or their fragments, recombinant VLPs could 
be used as a safe alternative for the vaccination in place of attenuated viruses. One of such 
example is commercial preparation Engerix® (GlaxoSmithKline) that is VLPs-derived vaccine 
made from HBsAg protein and is used globally for effective immunisation against Hepatitis B 
virus infection. However, worldwide licensed vaccines Cervarix® (GlaxoSmithKline) and 
Gardasil® (Merc & Co., Inc.) against cervical cancer can be considered as a more true VLPs 
because resembling structure identical to intact virions (for review see (Zhao et al., 
2014)).Vaccines are a mixture of VLPs formed by human papilloma virus (HPV) L1 protein, 
bearing L1 protein sequence variants from either type 16, 18 or type 6, 11, 16, 18 HPVs for 
Cervarix and Gardasil vaccines, respectively (Monie et al., 2008). 
The broad spectrum of VLPs sources provides material for the different types and sizes 
of VLPs, giving therefore possibility to choose for appropriate and best suitable type of VLPs, 
and also permitting us to change carrier if immune response is developed against it. 
1.1.2. Addressing 
Addressing of the VLPs with epitopes on their surfaces is one way how VLPs can be 
utilised. There can be mentioned numerous epitopes, added to the surface of the VLPs by using 
diverse ways of attachment. As one of the example can be mentioned addition of the HIV-Tat 
protein derived peptide, possessing strong internalisation properties (Vivès et al., 1997). 
Chemical attachment of the HIV-Tat (47-57) to the MS2 surface allowed internalization of 
VLPs into cells and release of functional in vivo packaged antisense RNA (Wei et al., 2009), 
using sulfosuccinimidyl-4-(p-maleimidophenyl)-butyrate reagent for binding of N-terminal 
cysteine in HIV-tat sequence. For protein chemical attachment there are actually four targets in 
protein structure – primary amines (-NH2), carboxyls (-COOH), sulfhydryls (-SH) and 
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carbonyls (-CHO). One approach is based on a fact, that particles contain bifunctional amino 
acids on the surface able to bind proteins by using crosslinking reagents as shown in 
abovementioned examples. If the VLPs surface does not contain such bifunctional amino acids, 
then other variant is chemical functionalization of the surface of virus-like particles, for 
example, using azide-alkyne click chemistry (Patel and Swartz, 2011).  
Chemical attachment can be used for binding of non-protein origin substances, for 
example, the company Cytos Biotechnology AG bound nicotine to Qb VLPs and induced strong 
immune responses in preclinical studies (Maurer et al., 2005). Another perspective substances 
(addresses) for targeted drug delivery and use in clinical applications are aptamers – short 
oligonucleotides for specific binding to target molecules (for review see (Pei et al., 2014; Ray 
and White, 2010), however they are jet not coupled to VLPs. 
For the specific ligand to work, appropriate receptor on the cell surface should be 
overexpressed, as was shown in example with one of the most commonly used ligand – 
transferrin (Daniels et al., 2012). The cellular binding and uptake of Qb virus like particles 
conjugated with transferrin was higher in case with transferrin receptor overexpressed cells, 
and the same study revealed positive correlation between ligand density on the particle surface 
and internalisation capacity into the cells (Banerjee et al., 2010). 
An interesting approach was tried by Gleiter and Lillie, where antibody-binding domain 
Z was fused to polyomavirus VP1 protein and was able to specifically bind and functionally 
present antibody trastuzumab. Such VLP / antibody complex provided delivery of packaged 
reported plasmid DNA to the ErbB2-positive tumour cell lines using receptor-specific 
endocytosis (Gleiter and Lilie, 2003). 
1.1.3. Packaging 
The other application is to use internal space of the particles – the inner content of the 
particles can be filled or exchanged with substances of interest, including not only nucleic acid 
sequences, but also organic structures – proteins (Kaczmarczyk et al., 2011), antibiotics (Brown 
et al., 2002), etc. and  even inorganic material – nanogold (Freivalds et al., 2014; Sun et al., 
2007), magnetic nanoparticles (Huang et al., 2011), etc. Jason Clark with group used 
bacteriophage lambda as a base for packaging of DNA into particles, and after incubation with 
them observed specific immunoresponse against appropriate protein expressed from packaged 
DNA sequence (Clark and March, 2004). Further experiments showed that bacteriophage 
packaged with HBsAg coding DNA sequence elicited stronger immuneresponse in comparison 
with commercial vaccine Engerix B, what is based on a recombinant HBsAg protein (Clark et 
al., 2011). Also between the promising substances to be packed are so called CpG 
oligonucleotides, known as immune stimulatory sequences (Krieg, 2012). On the other side, 
RNA sequences can be also packaged. As a successful example can be mentioned JC virus 
VLPs packaged with short hairpin RNA (shRNA) and acting as an inhibitor against synthesis 
of IL-10 (Chou et al., 2010). 
All those abovementioned approaches shows high versatility of VLPs usage purposes and 
areas, and many of them can be attributed to our used objects. 
1.2. Bacteriophage GA 
Bacteriophage GA belongs to the single stranded positive-sense RNA viruses – largest 
group of the VLPs candidates. One large and widely used class of them are RNA bacteriophages 
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capable to infect bacteria. They were among the first objects used to discover molecular biology 
processes. Bacteriophage MS2 was the first organism with fully sequenced genome (Fiers et 
al., 1976). RNA phages are divided into four serologic groups – I and II are members of 
Levivirus genus and III and IV belong to Allolevivirus genus. Main disparity between groups is 
presence of the A1 protein – read-through variant of the coat protein for the latter one group 
phages, necessary for production of viable phage particles (Hofstetter et al., 1974). 
Bacteriophage GA belongs to group II (Levivirus genus), and similarly as other RNA 
bacteriophages, consist from 180 coat protein monomers forming spherical particles. Coat 
protein forms dimers, which subsequently are arranged in icosahedral structure with 
triangulation number T=3. 
Bacteriophage GA genome consists from 4 genes, coding coat protein, maturation 
protein, replicase subunit and lysis protein (Inokuchi et al., 1986). Of main interest is coat 
protein, which expressed as recombinant protein can freely form virus-like particles. Coat 
protein monomers are 129 amino acids long and fold into three parts: five stranded anti-parallel 
β-sheets and to the capsids outer surface oriented N-terminal hairpin and C-terminal α-helice 
(see Figure 1) (Ni et al., 1996).  
 
  
Figure 1 Three-dimensional structure of bacteriophage GA coat protein monomer (adaptation 
from (Tars et al., 1997)). 
 
The C-terminal α-helice of one monomer fits in the groove between N-terminal hairpin 
and C-terminal α-helice of the second monomer, extending β-sheets into ten-stranded lattice 
and providing strong interaction between monomers. Therefore dimer structure can be 
considered as “building block”, forming capsid with approximate diameter 27 nm as for the 
other RNA phages (Fiers, 1979). 
Native formation of phage GA particles in cells involves also synthesis of maturation 
protein and packaging of phage specific genomic RNA. The studies on more explored phage 
MS2 showed, that originally, during phage maturation, genomic RNA is specifically packaged 
using small RNA hairpin – translational operator at the beginning of replicase gene (Hohn, 
1969). RNA hairpin structure for specific binding with coat protein is known also for phage GA 
(Gott et al., 1991). VLP formation from RNA bacteriophage coat protein is sufficient with 
expression of only coat protein in E.coli cells; for GA phage it was shown by (Lim et al., 1994). 
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In case when recombinant protein was expressed, it was shown packaging of unspecific nucleic 
material encapsidated during VLPs assembly (Pickett and Peabody, 1993). 
RNA bacteriophage inner content can be changed through in vitro repackaging (Wu et 
al., 1995). However, the binding of operator sequence can be used for directed packaging of 
foreign RNA in vivo, i.e., by simultaneously expressing MS2 bacteriophage coat protein and 
lacZ-operator RNA in E.coli cells (Pickett and Peabody, 1993). The in vivo packaging system 
for RNA phages on a basis of eukaryotic cells – yeasts S.cerevisiae – was firstly developed by 
Fastrez and Legendre on basis of phage MS2 (Legendre and Fastrez, 2005). Based on those 
authors work, MS2 VLPs with in vivo packaged HIV-1 gag mRNS were successfully tested for 
functionality of extracted RNA and VLPs were used for mice immunisation, inducing strong 
antibody response against HIV-1 p24 antigen (Sun et al., 2011). 
Despite the fact that originally maturation of coliphage GA occurs in presence of native 
phage genome in E.coli, self-assembly of the particles can be also achieved when bacteriophage 
GA coat protein is expressed in other organisms – in yeasts S.cerevisiae and P.pastoris 
(Freivalds et al., 2008). Based on other authors work, we tried to alter phage GA surface 
properties and inner content through different methods. 
1.3. Bacteriophage AP205 
Acinetobacter phage AP205 belongs to positive single-stranded RNA bacteriophage 
family Leviviridae, but infects Acinetobacter instead of Escherichia coli. It genome consists 
from three “main” genes, encoding maturation (A), coat and replicase subunit protein (Klovins 
et al., 2002). Unlike all other members of Leviviridae, phage AP205 genome bears two 
additional small open reading frames (ORF’s), one of which contains lysis protein expressing 
gene, but the function of second is unclear (Klovins et al., 2002). Although all proteins are 
necessary for proper virus maturation, in our case of main importance is the ability of the coat 
protein to self-assemble into VLPs (without help of other virus proteins). Cryo-EM analysis 
reveled the same icosahedral structure as for other small RNA bacteriophages, differing with 
slightly larger capsid size in 29 nm diameter (van den Worm et al., 2006). There are little of 
publications describing this phage, however present experiments show promising tendencies 
regarding of its possible use. 
Although virus-like particles are supposed to be as a drug delivery system (for review see 
(Georgens et al., 2005)) and different methods to receive immune response for specific peptides 
are described, the numerous amounts of publications proofs that virus-like particles can be 
successfully used as a basement for vaccine production (for reviews see (Gregory et al., 2013; 
Kushnir et al., 2012; Roldão et al., 2010; Zhao et al., 2013)). Specifically, one of our object - 
coat protein from Acinetobacter phage AP205 - can also be used as a carrier for foreign antigens 
to determine them to immune system (Bachmann et al., 2010), either conjugating protein 
sequences chemically (Bachmann et al., 2012) or using gene engineering methods (Bachmann 
et al., 2008). Latter one statement is possible also due to the ability of AP205 coat protein to 
carry large protein fragments at both C- and N-terminus, at the same time maintaining ability 
to self-assemble into capsids (Tissot et al., 2010). Attached sequences include variety of 
proteins – hormones (angiotensin II, gonadotropin releasing hormone), cell receptor fragments 
(CXCR4) etc., tolerating up to 55 amino acids insertions (Tissot et al., 2010). VLPs containing 
peptide p33 (CTL epitope) chemically coupled to coat protein and loaded with CpG to enhance 
their immunogenicity (Storni et al., 2004) induce not only strong primary CTL response, but 
also can be efficiently boosted with the same modified/packaged VLPs (Schwarz et al., 2005). 
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One of the latest advantage is obtained by using phage AP205 equipped with alpha-helical 
regions of HIV gp41 on the surface of VLPs, where after mice immunization strong specific 
humoral response and inhibition of native HIV virus infection was observed (Pastori et al., 
2012). 
1.3.1. Acinetobacter phage AP205 and WNV protein E domain III 
One of the perspective target for vaccination can be pathogenic arboviruses, specifically, 
member of Flaviviridae – West Nile virus (Ishikawa et al., 2014). Despite the fact that West-
Nile virus infection are mainly asymptomatic, symptomatic cases cause mild febrile illness (so 
called West Nile fever) an in rear cases neuroinvasive diseases (meningitis, encephalitis, etc.), 
yielding overall fatality rate near 4% (Lindsey et al., 2010). A lot of succesfull vaccine or 
vaccine candidates are developed for arboviruses, nevertheless for many of them (including 
West Nile virus) viable vaccines should be produced. In parallel to attenuated virus vaccines, 
novel approach in vaccine development is the use of enveloped VLPs (Pijlman, 2015). 
West Nile virus consists from nucleocapsid, formed from nucleocapsid protein (C) and 
genome RNA, and from envelope, formed from lipid membrane protein (M) and large envelope 
protein (E) together with host’s membrane (Murphy, 1980). As can be seen from crystal 
structure of WNV protein E (Figure 2), domain III are localized toward the outer surface of 
West Nile virus (Kanai et al., 2006). 
 
 
Figure 2 Crystal structure of the WNV protein E (adaptation from (Nybakken et al., 2006)). 
 
To proof the concept if outside located protein E domains can be used for immunological 
purposes, a recombinant protein from protein E domain III was expressed in E.coli, purified as 
insoluble protein, refolded and finally used for polyclonal antibody production. Although the 
expressed protein was not glycosylated (apart from the glycosylated protein in native virus) and 
VLPs cannot be considered as enveloped, obtained antibodies showed inhibition of WNV entry 
into Vero cells and C6/68 mosquito cells, and what is the most important - murine polyclonal 
serum inhibited infection with WNV (Chu et al., 2005). The same is proofed also in case where 
protein E domain III (EDIII) specific monoclonal antibodies were used (Liu et al., 2008). The 
sequence region most probably responsible for infection is so called DIII lateral ridge (DIII-lr) 
(Figure 3), where full inhibition of infection in vitro are observed after treatment with DIII-lr 
specific monoclonal antibodies (Nelson et al., 2008). 
 
12 
 
 
Figure 3 West-Nile virus protein E, circled regions shows epitopes specific for interaction with 
WNV neutralizing mAbs (adaptation from (Diamond et al., 2008)). 
 
Previous successful experiments, showing no need for post-translational modifications of 
protein E fragments, promoted the usage of this protein as an easy attachable epitope on the 
surface of VLPs. After chemical coupling of unmodified AP205 coat protein and purified fusion 
protein, consisting from fragment of domain III of the WNV E protein, a hexahistidine tag and 
cysteine containing linker, mice were immunized in order to obtain WNV specific antibodies. 
After immunisation with mixture of coat protein and abovementioned WNV protein fragment, 
similarly as in case when immunising with WNV protein alone, no specific WNV 
immunoresponse was detected. After isotyping, WNV specific antibodies obtained after 
immunisation with chemically coupled VLP-WNV complex, were IgG2a specific (Spohn et al., 
2010). This is opposite to the antibodies obtained after immunisation with WNV protein alone, 
where mainly IgG1 class antibodies are represented (Liu et al., 2008; Spohn et al., 2010). 
Together with the fact that with VLP-WNV complex immunised mice were able to survive 
admission of virulent WNV in lethal concentration, such complex of AP205-WNV can be used 
as attractive vaccine candidate for WNV prophylaxis (Spohn et al., 2010). 
1.4. Hepatitis B 
Hepatitis B virus genome encodes two viral genes S and C, forming two antigens – 
HBsAg and HBcAg, respectively. S gene codes three surface proteins – large (L), middle (M) 
and small (S), the last one is known to form particles with 22 nm diameter (Gerin et al., 1971). 
M and L proteins are prolonged variants of S protein, N-terminally containing prolongations 
with preS2 and preS1 sequences, respectively (for review see (Paul Pumpens, 2008)). 
Expression of surface antigen in E.coli cells have not lead to assembly of particles, but 
expression in yeast was successful (Hitzeman et al., 1983; Valenzuela et al., 1982), serving as 
a basis for vaccine development against Hepatitis B virus. Both vaccine products Engerix-B 
(GlaxoSmithCline) and Recombivax (Merck) are yeast-expressed non-glycosylated protein S-
derived particles. In order to acquire better immunological responses against Hepatis B virus, 
preS2 epitope and especially preS1 epitope for binding with hepatocyte receptors were attached 
to the S protein, yielding either full-length non-reconstructed M (GenHevac B, Pasteur) or M 
and L (Bio-Hep-B, BioTechnology General Ltd.) vaccines or Hepacare vaccine containing 
complete sequences of S and preS2 region and preS1 sequence 20-47. Many other attempts to 
improve current Hepatitis B vaccine on a basis of HBsAg are tried, involving DNA vaccines 
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and plant-expressed edible vaccines. Despite a complex and irregular lipoprotein structure of 
HBsAg formed VLPs, they are tried to be used as a vaccine candidates for other diseases (for 
review see (Paul Pumpens, 2008; Roose et al., 2013)). 
1.4.1. Structure of HBc 
Hepatitis B virus C gene codes at least four different polypeptides: p25, p22, p21, and 
p17 (Scaglioni et al., 1997), however only p21 (HBc monomer as such) codes for self-assembly 
capable protein and therefore is widely used as a target for VLP engineering. This so-called 
core protein monomer is 183(185) amino acids long and composed as two α-helical hairpins 
forming dimer with a four-helix bundle (Figure 4A). Dimers assemble in to two types of 
particles – T=4 particles from 240 molecules with diameter 34 nm (Figure 4B) and T=3 particles 
from 180 molecules with diameter 30 nm – observed as mixture of both size particles in electron 
micrographs (Cohen and Richmond, 1982). Core protein contains four Cys residues – Cys107 
is free thiol, Cys61 fully and Cys48 partly forms interchain disulphide bonds with another 
monomer and Cys183 forms disulphide bonds with monomer of another dimer (Nassal et al., 
1992; Zheng et al., 1992). However, replacement of all Cys to Ser showed no requirement of 
cysteine residues for assembly of replication-competent particles nor for envelopment of them 
(Nassal, 1992a). Fine structure of HBc particles was ascertained using X-ray crystallography 
(Wynne et al., 1999) and cryo electron microscopy (Yu et al., 2013). 
 
 
Figure 4 Three dimensional structure of hepatitis B core protein dimes (A) and core protein 
formed capsid (B) (adaptation from (Pumpens and Grens, 2001)). 
 
One of the intriguing part of the core protein is major immunodominant region (MIR) 
with central positions around 78-82 in the α-helical hairpin, forming tip of the spike on the 
capsid surface. The other interesting part of core protein is C-terminus, specifically, its property 
to withstand truncation of last C-terminal amino acids but at the same time retaining the self-
assemble capability of capsids (Birnbaum and Nassal, 1990). These C-terminal protamine-like 
arginine-rich domain lacking particles (so-called HBcΔ particles) were microscopically almost 
indistinguishable from full-length core protein formed particles, however they failed to 
accumulate nucleic material and therefore assembled as empty particles with impaired stability 
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(Crowther et al., 1994; Gallina et al., 1989). Therefore also efficient pregenomic RNA 
encapsidation was observed only in HBc VLPs truncated from C-terminus not more than till 
amino acid 164 (Nassal, 1992b). Also ratio between T=4 and T=3 particles in electron 
microscopy changed – full length core protein formed almost only T=4 symmetry particles 
whereas C-terminally reduced core protein generated T=3 symmetry particles (Wingfield et al., 
1995; Zlotnick et al., 1996). Initially Birnbaum and Nassal showed that C-terminal deletions 
till approximately 139-143 amino acids can be tolerated (Birnbaum and Nassal, 1990), and only 
later after creation and purification of a set of C-terminus absent mutants it was precised that 
140 amino acids are minimal length for particle assembly (Sominskaya et al., 2013). C-
terminally truncated variants HBcAg1-149 and HBcAg1-140 were more like “thin-walled” 
particles with much larger inner space when compared to “thick-walled” full-length particles 
(Newman et al., 2003). 
HBc protein is somehow different among other VLP carriers because of its high-level 
expression and effective particle formation in almost all known expression systems, including 
E.coli. This fact in combination with non-traditional three-dimensional structure of core protein 
in comparison to other viral capsid protein possibly leaded to extensive investigation of HBV 
core VLPs. 
1.4.2. HBc as exposition vectors 
The closer searches for the appropriate sites for insertions of foreign epitopes pointed 
toward MIR region and N- and C-terminus of core protein, not involving critical region for 
capsid assembly and being in good agreement with capsids three-dimensional structure (Wynne 
et al., 1999). 
N-terminal end of core protein was capable to withstand deletion of 4 amino acids or 
insertions of up to 50 amino acids. Among the numerous attachments some of the promising 
are chimeric particles carrying 23 amino acid fragment of extracellular domain of influenza A 
minor protein M2 (Neirynck et al., 1999) and fusion of 45 amino acids of the Puumala 
hantavirus nuclecapsid protein to the HBcΔ (Koletzki et al., 2000). 
Opposite to the N-terminal insertions where only full-length core protein VLPs can be 
used to achieve self-assembly, C-terminal attachments were to both the full-length and C-
terminally truncated HBc. Full-length HBc were capable to carry C-terminal fusions of up to 
55 amino acids from the HBV preS (Borisova et al., 1989) and SIV Env (Yon et al., 1992). As 
example for HBcΔ was shown C terminal fusions at positions 144, 149 and 156, by introduced 
sequences that exceeded even 100 amino acids (Pumpens et al., 1995). HBcΔ were appended 
C-terminally with HBV preS (Schödel et al., 1990) and S (Murray and Shiau, 1999), HIV-1 
gp120 and Gag (Grene et al., 1997), cytomegalovirus gp58 (Tarar et al., 1996), two epitopes 
from FMDV VP1 (Nekrasova et al., 1997). On the basis of HBcΔ even extremely long 
sequences from HCV core protein in length of up to 540 amino acids (and to some extent up to 
720) were successfully added without disrupting self-assembly capability of VLPs (Yoshikawa 
et al., 1993). Despite the good self-assembly of HBcΔ VLPs, after immunisation only moderate 
specific immune response against inserted epitopes are acquired. 
Of the main interest, however, are insertions into the MIR region, i.e., in the tip of the 
spike of the HBc molecule. Due to the capability to include long amino acid sequences without 
loss of self-assembly of VLPs and ability to guarantee high B and T cell immunogenicity, MIR 
region is favourite site of choice for foreign epitope insertions. Insertions of hantavirus 
nucleoprotein 120 amino acid (Koletzki et al., 1999) and 45 amino acid (Ulrich et al., 1999) 
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long fragments in MIR region of HBc generated not only strong immune response, but also 
ensured protection against virus challenge after immunisation, whereas N- and C-terminally 
fused analogues showed poorer responses. MIR insertions cover the same fragments of interest 
as with N- and C-terminal attachments, namely, 27 amino acid epitope of the preS (Schödel et 
al., 1992), 18 amino acids of VP2 protein form the human rhinovirus type 2 (Brown et al., 
1991), 30 amino acids of the SIV Env (Yon et al., 1992) and 25 amino acid (Brunn et al., 1993) 
and 43 amino acid (Borisova et al., 1996) sequences from V3 loop of the HIV-1 gp120 were 
inserted. Also recent finding showed successful construction of VLPs, bearing major rubella 
virus E1 protein (Skrastina et al., 2013), Mycobacterium tuberculosis CFP-10 protein 
(Dhanasooraj et al., 2013), etc., all capable to induce antibodies and protect against appropriate 
virus challenge. 
 preS epitopes were used to construct first multivalent particles, simultaneously 
containing different foreign sequences from preS1 and preS2 regions (Makeeva et al., 1995). 
Some special interest may be devoted to MIR deletion, where from numerous amount of data 
is deduced that region between glycines G73 and G94 can be used as a target for deletion, 
rearrangement and substitution (Borisova et al., 1996, 1997, 1999). Green fluorescent protein 
(GFP) and HBc chimeras retained both VLP self-assembly and GFP fluorescent capability, 
hence showing at least partially correct folding of 238 amino acid long protein inserted in MIR 
region and guided onto the surface of particles (Kratz et al., 1999). Similarly, fluorescent 
chimeric viral nanoparticles were obtained after addition of full length sequences of eGFP and 
DsRed proteins through glycine-rich flexible linker. This way attached fluorescent proteins 
showed higher fluorescence intensity than cognate fluorescent monomer proteins and also 
particles were more stable against photobleaching in vitro and in vivo inside mouse (Yoo et al., 
2012). 
Also mosaic particle production was adopted in HBc by introducing linker containing 
translational stop codons (UGA, or UAG) between C-terminally truncated HBcΔ and a foreign 
sequence (Koletzki et al., 1997). Elsewhere full-length preS-containing and native (helper) core 
vectors were co-transfected in E.coli cells, yielding mosaic VLPs (Kazaks et al., 2004). 
Chemical coupling as the attachment method was also tried on HBc particles using influenza 
virus M2e protein as a bound moiety, however induced antibodies after vaccination have not 
promoted virus-neutralizing effect (Jegerlehner et al., 2004). Another approach to overwhelm 
structural disorder of epitopes after chemical binding was tried by using non-covalent 
interaction between HBc spike and it specific peptide (“binding tag”) supplemented with 
multiple copies of the extracellular domain of the M2 protein of influenza virus (Blokhina et 
al., 2013). 
It can be concluded that robust structure and convincing assembly of the HBc VLPs 
allows successful self-assembly even after insertion of long sequences in various places of coat 
protein monomer. 
1.4.3. HBc mediated immunogenicity 
The matter of fact that HBV patients develop strong and long-lasting humoral anti-HBc 
response (Hoofnagle et al., 1973) demonstrate extremely high immunogenicity of the HBc 
protein. HBV core protein in native virus is as an internal antigen, however strong B-cell, T-
cell and cytotoxic T lymphocyte (CTL) response (especially for epitope 18-27) promotes 
therapeutic vaccine searches also in this field (Livingston et al., 1999). Therefore it is not 
surprisingly that combination of HBV preS and S epitopes on the HBc carrier are tried to be 
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used for further HBV vaccine development (as examples see (Chen et al., 2004; Kazaks et al., 
2004; Yang et al., 2005; Zhao and Zhan, 2002)). As another immune system affecting agents 
can be mentioned CpGs – DNA sequences rich in non-methylated CpG motifs greatly 
facilitating immune responses and inducing through strong T-helper and CTL response, and 
therefore can be considered among most promising adjuvants today. The packaging of CpG 
sequence in VLPs allows to overcome some drawbacks – unfavourable pharmacokinetics and 
vulnerability to DNase I digestion, at the same time ensuring strong response against CTL 
epitopes attached onto VLPs. 
1.4.4. HBc as delivery vectors 
HBc inner content deprivation 
The inner space of full length HBc protein VLPs is filled with RNA that mainly 
corresponds to core protein mRNA (Birnbaum and Nassal, 1990). Up to the 156 amino acid 
long core protein formed particles can be characterized as almost empty (Sominskaya et al., 
2013), however, packaging of desirable (required) nucleic acid material is difficult. Therefore 
another way is to seek for methods to empty full-length HBc particles needed (necessary) for 
repackaging of their inner content. Today two methods are known – osmotic shock based and 
through dissociation / reassociation of HBc. The first one method is more like “budding” of 
VLPs by in low ionic strength buffer solution, supplemented with RNAse A treatment (Kann 
and Gerlich, 1994). This method for obtaining empty HBc particles was later improved and 
characterized in details (Broos et al., 2007). However, logical limitation of this method is due 
to the RNAse A that permits the packaging of nucleic acid sequences of RNA origin. However, 
this method with slight variations was successfully used to package short CpG 
oligodeoxynocleotides in chimeric HBc VLPs harbouring tumour-associated MAGE-3 epitope 
(Kazaks et al., 2008). When micrococcal nuclease was used instead of RNAse A, beside the 
foreseen eating out the inner content of particles the significant degradation of HBc VLPs was 
observed (Newman et al., 2009). Another approach to obtain empty particles with help of 
nucleases was construction of chimeras from HBc core and enzymatically active region of 
17kDa Staphylococcus aureus nuclease, that was able to produce empty particles upon protein 
synthesis in cell (Beterams et al., 2000). 
The re-association was promoted after addition of oligodeoxynucleotides, poly-glutamic 
acid and polyacryl acid, nevertheless polylisine, polyethyleneimine and inositol triphosphate 
induced no capsid assembly. C-terminally truncated variants after treatment according to this 
method was not affected (Newman et al., 2009). 
Fairly different method to get empty particles without nucleases was elaborated through 
core particle chemical disassembly. Guanidine HCl or urea treatment was used to disrupt 
truncated (3-148 amino acids) HBc particles, followed by packaging of GFP protein into VLPs 
by subsequent removing of denaturant by dialysis (Lee and Tan, 2008). Guanidine HCl and 
LiCl buffer was used to produce core dimers, that were either assembled as empty particles at 
higher ionic strength buffer or packed with various RNA samples (Porterfield et al., 2010). 
In studies with bacteriophage MS2 viral capsids alkaline treatment of VLPs was used in 
order to remove genomic material (Hooker et al., 2004). Based on data about extreme chemical 
stability of HBc capsids in pH range 2 - 14 (Newman et al., 2003) we worked out our method 
for production of empty HBc VLPs through alkaline treatment of purified particles. 
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Binding and internalization of HBc VLPs 
The possibility of HBc VLPs to interact with cells and to be internalized into cells were 
studied by several authors. In Kann and Gerlich group were used digitonin permeabilized cells 
to assess that E.coli expressed and in vitro phosphorylated HBc VLPs go into cells, reach the 
nucleus of the cells and bind to nuclear pore complexes (Kann et al., 1999). The detailed 
investigations regarding HBc VLP binding to cells and internalization were carried out by 
Vanlandschoot group (Vanlandschoot et al., 2005), who showed no binding of C-terminus 
deficient (lacking 145-183 amino acids) and strong binding of full-length HBc VLPs to various 
cells that was completely blocked by using heparin, heparin sulfate or chondroitin sulfate B. 
These observations shows crucial role of arginine-rich protamine-like domain for binding 
of capsids to glucosaminoglycans expressed on cell surface. The RNAse treatment of particles 
enhanced binding of full-length HBc even more and, on the base of previous statement, authors 
hypothesize that after removal of packaged RNA, protamine-like domains are easier accessible 
by long sugar (glycosaminoglycan) chains on surface of cells (Vanlandschoot et al., 2005). 
Cooper and Shaul showed internalisation of full-length HBc VLPs into broad spectrum of cells, 
that was determined using fluorescently labelled oligonucleotide packaged in to the particle 
(Cooper and Shaul, 2005). Following experiments showed heparin and chlorpromazine but not 
nystatin inhibition of binding, thereby specifying that type of internalization for unmodified 
HBc particles are energy-dependent clathrin-mediated endocytosis. Additionally, confocal 
microscopy pointed that endocytosed HBc particles are targeted to lysosomes (Cooper and 
Shaul, 2006). 
Meanwhile intact cell membrane trespassing of whole HBc VLPs was achieved after N-
terminal fusion with protein transduction domains (PTDs), specifically, 12 amino acid long 
translocation motif from HBV surface protein. Such particles were capable to cross the cell 
membrane and move toward nucleus, bearing HBsAg or eGFP sequence. Clear ability of PTD-
driven internalization was seen in ultra-thin sections in electron microscopy and in confocal 
microscopy (Brandenburg et al., 2005). One of recent findings shows cellular uptake of HBc 
VLPs when using fibronectin-binding fragment of B.burgdorferi BBK32 protein sequence 
inserted in MIR region (Ranka et al., 2013). 
Last advances in HBV core protein modification leads to development of so-called Split 
Core technology. The native core monomer was genetically split in MIR tip between P79 and 
A80 via introduction of stop and start codons. Both coreN and coreC proteins expressed in cells 
formed capsid-like particles, capable to fuse heterologous sequences in sterically unrestrained 
fashion (Walker et al., 2011). This perspective system was recently used to successfully attach 
hepatitis C virus hypervariable region 1, capable to induce cross-neutralizing antibodies against 
hepatitis C after immunization of mice (Lange et al., 2014). 
Also, another one ingenious approach is tandem fusion where both HBc dimer-forming 
monomers are joined together as single polypeptide. Therefore, insertion of large heterologous 
sequences in only one of the MIR spikes can be better tolerated in terms of VLP formation, 
because foreign sequences on particle surface are “diluted” two-fold if compared with full-
epitope VLPs where each core protein monomer contains additive. This technological solution 
was used to express tandem HBc protein either in bacteria (E.coli) or plants (N. bethamiana) 
unmodified and also supplemented with full sequence of GFP or camelid single-domain 
antibody fragments by inserting them in second MIR site of tandem polypeptide (Peyret et al., 
2015). 
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2. Materials and methods 
2.1. Plasmid construction and protein expression 
For E.coli cells, plasmids containing trp promoter were used for AP205 phage derived 
coat protein and hepatitis B core protein expression. AP205 coat protein containing plasmids 
were constructed on the basis of plasmid pAP283-58 (Tissot et al., 2010). Bacteriophage GA 
coat protein containing plasmid, as well as HBV core protein containing plasmids were 
constructed on the base of pGEM-1 based plasmid (Freivalds et al., 2008). All construction 
procedures were performed according standard cloning procedures described elsewhere, 
specifically – fragments were either cut out by using restriction endonucleases or cloned out 
using PCR, whereas point-mutants in case of HBV core protein was obtained by standard 
mutagenesis procedures. 
All plasmids were replicated in E.coli strain RR1; for expression of GA and AP205 coat 
protein were used strain JM109 and for expression of HBV core protein were used strains K802 
or BL21. Therefore that AP205 constructions contained either amber or opal suppression stop 
codons, they were expressed in modified JM109 strains containing helper-plasmids pISM579 
and pISM3001. In case of WNV protein, it gene sequence was inserted in pET28+ plasmid 
under T7 promoter and grown in E.coli cells in strain C2566, applying IPTG as promoter 
inducer. For other E.coli transformed plasmids, growth medium was supplemented with 
tryptophan as a protein synthesis inducer. 
In case of yeast-expressed constructions, shuttle-vector plasmids pESC-URA and pFX 
were used. For construction purposes, both type of plasmids were transformed in E.coli cells in 
strain RR1. Plasmid pFX was transformed in yeast S.cerevisiae in strain AH22 according 
(Freivalds et al., 2008) methodology. Plasmid pESC-URA contains two opposite-direction 
promoters GAL1 and GAL10, suitable for both expression of two types of proteins for mosaic 
particle production and for in vivo packaging. All constructions procedures are the same, as in 
case with E.coli expression meant constructions. pESC-URA based plasmids were transformed 
in yeast S.cerevisiae strain YPH499 competent cells using Yeast Transformation Kit (provided 
by and according Sigma-Aldrich protocol), then positive clones were selected in uracil-free 
agarised synthetic dextrose minimal medium and grown for expression in uracil-free synthetic 
galactose minimal medium. Yeast P.pastoris was used for expression of HBV core protein and 
obtaining of VLPs (Freivalds et al., 2011). 
2.2. Purification of VLPs or protein 
VLPs from E.coli cells were purified by suspending cells in lysis buffer and sonicated by 
using 22kHz ultrasound, whereas yeast cells were additionally disrupted by subjecting through 
French press and vortexing with glass beads. Further purification procedures varied between 
each type of VLPs, however, for AP205- and GA- based VLPs, lysate was centrifuged to 
sediment debris and supernatant was then chromatographed through gelfitration 
chromatography (using Sepharose CL-2B and/or Sepharose CL-4B), ion-exchange 
chromatography (using Sephadex A50) un sucrose density gradient ultracentrifugation. All 
concentrations between purification steps were done by using Amicon ultrafiltration devices or 
in dialysis tubes against dry Sephadex G-100 for AP205 or GA VLPs, respectively. AP205 
working buffer was TEN, but GA VLPs as well as core VLPs needs addition of NaCl (i.e., 
TEN+0.5M NaCl was used). As one of the methods to distinguish VLPs and nucleic acids or 
19 
 
complexes of them was based on CsCl density gradient, relying on different densities of 
proteins and nucleic acids. 
Fairly different is purification procedure for core VLPs, where cell lysate after 
ultrasonication was supplemented with urea till 0.45M, then centrifuged and supernatant was 
precipitated with ammonia sulphate in two steps, collecting the part that sediments in saturation 
range from 10% till 60%. Then subsequently Sepharose CL-2B and Sepharose CL-4B 
chromatography columns were used, concentrating appropriate fractions with ammonia 
sulphate (at 60% saturation). Next, material was dialysed against water and subjected through 
Sephacryl S-300 gelfiltration column using 0.1 M Na2CO3, 2 mM DTT as the eluent. Last step 
is essential for emptying of HBV VLPs. 
WNV protein was extracted from cell lysate debris using 7M urea. To get rid of nucleic 
acid contaminants, either DEAE-cellulose ion-exchange chromatography or ammonia sulphate 
precipitation was used. Then refolding in presence of 2M urea + 0.5M arginine-HCl (pH8.0) 
and gelfiltration through Sepharose CL-4B column was done. 
2.3. Detection of protein / VLPs and nucleic acids 
During VLP and protein purification, detection of protein was done mainly using 
polyacrylamide gel electrophoresis (PAGE) and quantity was assessed by spectrophotometric 
methods (according (Ehresmann et al., 1973)). Western blot and Ouchterlony double-radial 
immune diffusion were used to immunologically approve presence of right one protein and 
electron microscopy was used to show VLPs morphology. For VLPs or their aggregate 
detection as one of the methods was used dynamic light scattering (DLS). 
Native agarose gel electrophoresis (NAGE) was used to assess movement of VLPs and 
also if nucleic acids are alone or in complexes with VLPs. The inner content of VLPs were 
extracted using phenol/chloroform (1:1), then diethyl ether washed and finally precipitated with 
ethanol. Extracted content was tested on NAGE for DNA fragments or formaldehyde agarose 
gel electrophoresis (FAGE) for RNA fragments integrity. As a better alternative to FAGE was 
used also capillary electrophoresis system 2100 Bioanalyser (Agilent Technologies). Extracted 
RNA samples were analysed using reverse transcription PCR reaction to prove the presence of 
gene, and if necessary, qPCR was used to precise the relative amount of packaged gene inside 
particles. For PCR reaction, reverse transcription with random hexamer, oligo(dT) and gene-
specific primers were used to produce cDNA, that used for PCR as a template with gene 
specific-primers. 
2.4. Deprivation of HBc particles and re-packaging 
To obtain empty particles, alkali treatment of HBc VLPs was used. Purified fractions after 
Sephacryl S-300 column were intensively dialysed against “alkaline” solution (0.1 M Na2HPO4 
/ Na3PO4, 0.65 M NaCl, pH 12 (NaOH)) at +37°C for 18 h. Then dialysis medium was 
exchanged to a restoration buffer (0.1 M Na2HPO4, 0.65 M NaCl, pH 7.8 (H3PO4)) at room 
temperature and at +4°C. Additional separation of aggregates and empty particles was done 
onto a Sepharose CL-4B column. Change of absorbance ratio A260/A280 and lack of EtBr 
fluorescence and presence of Coomassie blue staining in NAGE analysis demonstrated 
formation of empty particles. 
Packaging of empty VLPs were conducted by mixing empty HBc particles with RNA or 
short DNA fragments. Reconstruction procedure included subsequent dialysis against 7 M urea 
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+ 1 M NaCl at +4°C for one hour followed by dialysis against multiple portions of fresh 
restoration buffer and was used particularly for long DNA fragments and plasmids. 
2.5. Immunization with VLPs and proteins 
Female BALB/c mices were immunised with both WNV-DIII fragment bearing VLPs 
and also with WNV protein. Immunisation was done on days 0, 14 and 28 with 25µg of protein 
per injection, and at the day 42 serum was taken. In parallel, immunisation experiment was 
expanded with samples, supplemented with adjuvants Alum and SiO2. Direct ELISA was done 
according standard protocols, first, by coating plates with DIII protein, then, second, incubating 
them with immunised mice serum followed by incubation with horseradish peroxidase 
conjugated anti-mouse antibody, and, finally, determining the titre. 
IgM and IgG subtypes were detected with direct ELISA, except that in goat/sheep 
produced monoclonal antibodies against different mouse antibody subclasses were sorbed on a 
plate and then incubated with immunised mice serum followed by peroxidase conjugated anti-
goat/sheep IgG antibody. 
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3. Results and discussion 
3.1. Bacteriophage GA VLPs 
The abovementioned possibilities to use phage GA as a delivery and exposition vector 
were used in our experiments (Strods et al., 2013). 
Previous possibilities to use RNA bacteriophages as a delivery and exposition vectors 
were used also in case with phage GA recombinant particles (Strods et al., 2013). First, we 
improved coat protein expression and therefore also overall VLP yields in S.cerevisiae cells by 
rewriting phage GA coat protein nucleotide sequence to the yeast cell more optimised codons. 
Nucleotide sequence was substituted according built-in yeast S.cerevisiae codon table in 
software package Vector NTI 10.0.1 (Invitrogen). Amino acid sequence was not changed and 
remained the same as described in (Tars et al., 1997).  Albeit the previous research (Freivalds 
et al., 2008) suggests to take more productive yeast types, our experiment design demanded 
two-promoter system for simultaneous processing of two genes. Therefore we used expression 
vector pESC-URA and created workaround through codon optimisation. The strategy was 
advantageous and VLPs yield level was comparable to those obtained by using formaldehyde 
inducible promoters (vector pFX using S.cerevisiae) or vector pPIC3.5K using P.pastoris 
(Freivalds et al., 2008). 
Second, we used previous experience (Rūmnieks et al., 2008) and produced in vivo 
packaged particles containing GFP and interleukin-2 mRNA. After thorough purification of 
particles, inner content was extracted and tested for presence of either GFP or IL-2 gene via 
reverse transcription PCR. This method does not allow to estimate specificity of packaging of 
our gene of interest, however, from our and previous (Rūmnieks et al., 2008) study we can 
deduce that large proportion of non-specific RNA are present in the particles. Therefore, as a 
continuation of (Strods et al., 2013) work, we set a task for us to improve the encapsidation rate 
through using the replication origin of MS2. Previously, MS2 and GA phage coat protein and 
translational operator interaction experiments revealed that of main importance are amino acids 
at positions 43, 55, 59, 83, 87, 89 (Lim et al., 1994) and 29, 66 (Lim and Peabody, 1994), and 
on the base of them single-point (S87N, K55N, R43K) and double-point (S87N+K55N and 
S87N+R43K) mutations were introduced in GA coat protein (Strods et al., 2015, manuscript 
submitted, see appendix). Parallel, advantage of two promoter system was used and in all 
constructions under second promoter was inserted GFP gene coding sequence. Additionally to 
those abovementioned variants was synthesized construction where GFP sequence are 
complemented with MS2 operator sequence. The idea to use MS2 tagging (Chubb et al., 2006) 
and tethering (Keryer-Bibens et al., 2008) techniques is based upon strong and highly-specific 
MS2 protein – MS2 operator interaction. Analysis of inner content from thoroughly cleaned 
VLPs revealed that all VLPs packed GFP mRNA. With MS2 operator supplement, quantity of 
packaged GFP mRNA was relatively higher, showing expected specificity. Despite the 
considerable specificity of gene packaging directed by MS2 operator, VLPs still continue to 
package its own GA coat protein mRNA and possibly some unspecific sequences (Strods et al., 
2015, manuscript submitted, see appendix). 
And the third, we used genetic engineering methods to covalently attach HIV-Tat (48-60) 
and WNV-DIII amino acid sequences to the GA coat protein. The third task was accomplished 
by simultaneous expression of native coat protein and prolonged coat protein through usage of 
dual promoter system, therefore producing mosaic virus-like particles. Foreign sequence was 
attached either at N-terminus or C-terminus of coat protein for HIV-Tat or WNV-DIII proteins, 
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respectively. Purified protein from phage AP205 coat protein genetically fused with WNV-DIII 
was used for production of polyclonal antibodies in mice, and then with the help of these 
antibodies proper exposition of WNV-DIII sequence onto the surface of mosaic particles was 
shown (Strods et al., 2013). 
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Conclusion 
Bacteriophage GA coat protein based VLP production in yeast two-promoter expression 
system was optimized by changing nucleotide sequence according S.cerevisiae preferable 
codons without changing amino acid sequence. Mosaic particles containing GA coat protein 
and coat protein N-terminally supplemented with HIV-Tat (48-60) or C-terminally 
supplemented with WNV-DIII (296-406) sequence were produced. WNV-DIII sequence 
placement on the surface of VLPs was proofed by anti-WNV-DIII antibodies. To obtain 
particles packaged with desired nucleic acids, in vivo packaging method was tested by 
simultaneously expressing GA coat protein and IL-2 or GFP mRNA. Although the mRNAs of 
interest were packed, we tried to improve packaging specificity through adding MS2 operator 
sequence to mRNA and using modified GA VLPs, mimicking MS2 operator binding site. 
Nevertheless the packaging specificity was increased, still coat protein mRNA and possibly 
other RNA sequences were present in VLPs. 
Thesis 
 Yeast-produced bacteriophage GA coat protein derived VLPs are capable to form mosaic 
particles, including HIV-Tat (48-60) sequence and immunologically competent region of 
WNV domain III. 
 Two-promoter system based on plasmid pESC-URA was used for in vivo packaging of IL-
2 and GFP mRNA into GA coat protein particles; the packaging specifity was remarkably 
improved by supplementing MS2 operator sequence to GFP mRNA and using GA VLP 
mutants that mimicks MS2 operator binding site, however particles still contained its own 
coat protein mRNA. 
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3.2. Bacteriophage AP205 VLPs 
Inspired by possibility to obtain specific antibodies using chemically coupled WNV 
epitope (Storni et al., 2004), we tried to make covalent attachment of WNV epitope by 
genetically fusing WNV protein to the C-terminus of bacteriophage AP205 coat protein 
(Cielens et al., 2014). Theoretically this method is better due to the uncompromised location of 
foreign sequence (EDIII), especially because EDIII sequence contains two cysteine at positions 
305 and 336 (Figure 5) and therefore binding site to coat protein may alter. 
 
QLKGTTYGVCSKAFKFLGTPADTGHGTVVLELQYTGT 
      300            310            320            330 
DGPCKVPISSVASLNDLTPVGRLVTVNPFVSVATANA 
           340            350            360 
KVLIELEPPFGDSYIVVGRGEQQINHHWHKSGSSIGK 
370            380            390            400 
 
Figure 5 Amino acid sequence of the WNV envelope protein domain III (adaptation from 
(Nybakken et al., 2006)). Grey shaded sequence corresponds to the β-sheets A, B, C, E, F and 
G, respectively; in bold are denoted cysteine residues in positions 305 and 336. 
 
Whole sequence from protein E domain III (specifically, amino acid residues 296-406) 
from West-Nile virus New York strain 385-99 were cloned at the C-terminal end of AP205 coat 
protein, separated by short linker and amber or opal suppressor. Mosaic VLPs synthesis was 
used as an alternative instead of full-epitope exposition on VLPs surface because self-assembly 
of C-terminal AP205-DIII fusion was failed both in vivo and in vitro (after refolding attempts) 
(Cielens et al., 2014). 
After expression in E.coli cells carrying appropriate suppressor tRNA genes, AP205 coat 
protein based mosaic VLPs were produced, purified and mice were immunised in combination 
without or with different adjuvants – Alum or SiO2 (Cielens et al., 2014). Immunisation data 
were generally similar for both AP205-op-DIII and AP205-am-DIII suppression variants. 
Along with VLPs, refolded WNV EDIII recombinant protein was also used for mice 
immunization. Direct ELISA tests showed that after immunisation without adjuvant addition, 
AP205-DIII VLPs induced evident anti-DIII response if compared with weak immunogenicity 
after immunization with DIII polyopeptide. Addition of adjuvants enhanced immune responses 
very strongly, reaching almost equal antibody titre levels after two boosts on 42nd day for both 
AP205-DIII VLPs and DIII peptide. As main positive aspect is switching of antibody subtype 
from IgM in case of DIII protein toward IgG in case of mosaic AP205/DIII VLPs in both 
adjuvant-free and adjuvant-added immunization variants (Cielens et al., 2014). 
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Conclusion 
Our antibody titres obtained after immunization with genetically fused WNV protein 
fragment were comparable to those obtained by immunization with AP205 VLPs carrying 
WNV sequence through chemical attachment (Spohn et al., 2010). Chemical binding procedure 
is tricky because of two cysteines in WNV sequence, whereas genetic fusion is easier for 
production of particles at the same time providing determined place and orientation of attached 
sequence. Abovementioned facts shows possible role of such mosaic VLPs to be used as a 
perspective and safe prophylactic vaccine against WNV infection. 
Thesis 
 Mosaic particles containing phage AP205 coat protein and protein C-terminally fused with 
111 amino acids long WNV envelope protein E domain III sequence can be obtained in 
E.coli expression system. 
 Bacteriophage AP205 WNV DIII sequence containing mosaic VLPs elicit WNV specific 
antibody response after immunisation in mice. 
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3.3. Hepatitis B virus core VLPs 
Hepatitis B virus core protein formed recombinant particles were obtained by expressing 
full-length (183 amino acids) core protein either in bacteria (E.coli) or yeasts (P.pastoris). In 
E.coli were expressed also four point-mutants with amino acids 75, 77, 79 and 80 substituted 
by lysine residues, all capable to self-assemble into VLPs (Figure 6). 
 
 
Figure 6 Amino acid sequence and spatial structure of wild-type HBc protein monomer and 
four lysine mutant variants. (A) Primary structure of the central part of spike of the HBc 
molecule, (B) 3D structure for the spikes of wild-type HBc protein monomer and four lysine-
exchanged HBc mutants with appropriate innate amino acid marked red. The crystal structure 
3D projections of the tips of MIR spikes are from recombinant bacteria-produced HBc VLPs 
(Wynne et al., 1999). 
 
To our knowledge, two “innate” lysines in core protein are located at the positions 7 (N-
terminus) and 96 (middle of spike), therefore additional lysines exposed on the tip of the MIR 
region possibly could be used for chemical coupling purposes. During thoroughly purification 
procedures, sodium dodecyl sulfate PAGE (SDS-PAGE) and NAGE were used to control 
process and ascertain for quality of preparations. Point-mutant VLPs after analysis in NAGE 
showed slower movement that they both (bacteria-/yeast-produced) un-mutated counterparts. 
Especially can be mentioned HBc-K77 mutant, bearing rather positive charge at pH7.5 and 
pH8.3 and therefore moving even backwards in NAGE (Strods et al., 2015a). After purification, 
four novel VLPs were obtained for addressing purposes. In one case for HBc-K75 VLPs, T 
lymphocyte specific aptamer sgc-8 containing 3’ attached thiol group was chemically coupled 
to particles (Renhofa et al., 2014). 
To obtain empty VLPs suitable for encapsidation of various materials, all 
abovementioned VLPs were subjected to alkaline treatment at pH12 – procedure (described in 
Materials and Methods) to get nucleic acid empty HBc particles without impairing their 
structure. Despite the simplicity of method, empty VLPs needs to be purified through 
gelfiltration chromatography in order to separate aggregates from discrete empty capsids. In all 
cases after chromatography empty non-aggregated bacteria- and yeast-produced particles as 
well as all mutant (HBc-K75, HBc-K77, HBc-K79 and HBc-K80) particles were obtained. In 
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two cases for mutant VLPs HBc-K75 and HBc-K77 increased disposition for aggregate 
formation was shown (Strods et al., 2015a). 
Our further interest was devoted only to this “qualitative” part, particularly analysing 
them by wide variety of methods, including optical absorbance measurements, SDS-PAGE, 
NAGE at different pH, dynamic light scattering (DLS), electron microscopy (EM), monoclonal 
HBe/anti-HBe and HBc/anti-HBc kits and Ouchterlony’s double radial immune diffusion tests. 
DLS measurements showed size and homogeneity of empty particles similar to full ones, SDS-
PAGE and EM analysis proofed integrity of core protein and capsids, respectively. 
Despite the fact that EM can be used to discriminate between intact and empty particles, 
we used other methods – mainly optical absorbance measurements and NAGE analysis. 
Absorbance spectra analysis of empty bacteria-source and yeast-source particles showed ratio 
A260/A280 approximately 0.7, indicating absence of nucleic acids comparable to pure protein 
(HBc protein dimers analysed by (Porterfield et al., 2010)). NAGE analysis was also used to 
proof the loss of nucleic acids by comparing ethidium bromide and Coomassie blue stained gels 
for both alkaline un-treated and empty HBc VLPs. Movement of empty particles was generally 
slower (less negatively charged) for both bacteria- and yeast-produced VLPs in almost all tested 
pH conditions if compared with native particles, once again confirming the lack of inner 
negatively charged RNA filling in empty ones (Strods et al., 2015a). It can be also noticed that 
empty yeast-produced HBc VLPs were faster moving in NAGE compared to E.coli expressed, 
possibly due to the yeast provided phosphorylation (Freivalds et al., 2011). Alkali treatment 
method was used to make empty phage origin VLPs – for MS2 (Hooker et al., 2004) and PP7 
(Tumban et al., 2013). 
Empty HBc VLPs were combined with different types of RNAs and DNAs, using either 
simply mixing or urea scarification step for disruption and reassembly of particles. First, E.coli 
tRNA and rRNA bound firmly with both empty bacteria- and yeast-produced VLPs. Our 
experiments pointed to the lower packaging capability of yeast-derived VLPs compared with 
bacteria-produced ones, possibly due to the occupied inner compartment by phospho groups. 
Specifically, each bacteria-produced empty VLP seized almost 25 tRNA molecules whereas 
yeast-produced – less than 10 (Strods et al., 2015a). This fact corresponds also to nucleotide 
content in non-emptied particles, wherein bacteria-produced contains approximately 636 nt per 
particle more that yeast-produced, according to our optical density based calculations from 
simplified (Porterfield and Zlotnick, 2010) method. RNA packaged particles demonstrated 
similar NAGE and DLS pattern as native recombinant particles, however, phenol extraction of 
packaged material clearly demonstrated strong RNA degradation, determined by formaldehyde 
agarose gel electrophoresis, capillary electrophoresis and formaldehyde-PAGE. In comparison 
– RNA from recombinant bacteria-produced VLPs contained much longer fragments. Despite 
this fact, we packaged in vitro synthesized mRNA and after sequencing of extracted (and 
degraded) material with next-generation sequencing technology, at least 86.77% were mRNA 
specific sequences. There are known that nucleoprotein from Lassa and Tacaribe viruses and 
from Crimean-Congo haemorrhagic fever virus possess exoribonuclease (Hastie et al., 2011; 
Jiang et al., 2013) and endodeoxyribonuclease (Guo et al., 2012) activity, respectively. We 
assume that our empty particles also bear some kind of nuclease activity and thereby proposal 
for future would be packaging of native HBV genome, possibly, able to overcome this “face-
control”. 
Second, DNA starting from short oligos to large plasmids were used. 
Oligodeoxynucleotides (ODNs) in length 21 and 63 nucleotides after mixing in large 
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superiority with empty particles showed the same high level packaging as in case with RNA, 
favouring bacteria-produced VLPs (Figure 7). 
 
 
Figure 7 Contact titration of bacteria-produced (left) and yeast-produced (right) HBc VLPs by 
ODN63 at appropriate ODN molar superiority over VLP: 10 (2), 20 (3), 30 (4), 40 (5), 50 (6); 
appropriate empty HBc VLPs were used as a control (1). 
 
Packaged VLPs resisted NAGE and CsCl and sucrose density centrifugations. For larger 
DNA fragments urea-treatment was used, and opposite to ODNs, long DNA fragments or 
plasmid DNA formed large complexes in molar superiority of empty VLPs. Those large 
complexes were seen in DLS, held in wells in NAGE and in EM they looked like chains, but at 
the same time DNA was protected against DNase cleavage. To explore the capacity of 
packaging functional sequences, empty VLPs were packaged at equimolar ratios with a set of 
different length discrete DNA fragments and then tested for DNAse resistance. Phenol 
extraction revealed the intactness of packaged 1289 base pair fragment but not the 1737 base 
pair fragment. This border of packaging (between 2578 and 3474 nucleotides) is nearly to our 
calculated theoretical packaging of 3844 and 3208 nucleotides per particle for bacteria- and 
yeast-produced HBc VLPs, respectively. This outcome could encourage in future for packaging 
of transcription/translation capable genes of interest. 
To test the possibility to use HBV core VLPs as an immunisation moiety, mice were 
immunised with “native” HBc VLPs, empty HBc VLPs and re-packed with CpG HBc VLPs. 
Antibody titres on the 10th day were markedly higher for both bacteria-produced HBc VLPs 
and bacteria-produced with CpG re-packed HBc VLPs, but not for the empty bacteria-produced 
VLPs, however, at 28th day titres were equilibrated. Antibody isotyping showed markedly 
higher IgG1 and lower IgG2 antibody repertoire for empty VLPs, whereas IgG2 antibodies 
were more represented in non-empty HBc VLPs, especially in CpG containing. More 
convincible immune response was seen in INF-γ ELISpot after stimulation of lymphocytes, 
obtained from mice immunised with CpG-containing VLPs, if compared with HBc VLPs or 
empty HBc VLPs (Strods et al., 2015b). 
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Conclusion 
Strong alkaline treatment can be applicable for HBc VLPs without impairing capsid structure, 
but at the same time being sufficient for wiping out the inner content of the particle. Empty 
particles are capable to package short nucleic acid fragments either RNA or DNA by simple 
contact, however long DNA fragment packaging can be achieved only after restoration of 
particles by using urea treatment. Fixed length DNA fragment was able to be packed in one 
particle if its length was 1289 bp, but not if it was 1737 bp. After packaging, DNA was protected 
from DNAse ifluence, whereas RNA after packaging and extraction appeared to be strongly 
degraded. All lysine bearing point-mutant HBc-75K, HBc-77K, HBc-79K and HBc-80K 
formed VLPs were capable to withstand alkali treatment and to package nucleic material. 
Lysine residues on the spike tips can be used for chemically provided attachments, therefore 
allowing addressing of particles. 
 
Thesis 
 Single-point mutations N75K, E77K, P79K and I80K in HBV core protein allow formation 
of particles morphologically indistinguishable from natural recombinat capsids. 
 Alkali treatment based technology can be used for depletion of HBV core VLPs inner 
content and obtain empty particles for bacterial, yeast and all four point-mutants HBc-75K, 
HBc-77K, HBc-79K and HBc-80K. 
 Empty HBc VLPs can package nucleic material either by direct contact incubation or 
through restoration in urea and refolding. 
 Empty HBc VLPs package, but remarkably degrade RNA material. 
 DNA material packaged in empty HBc VLPs is protected from DNAse I cleavage. 
 HBc VLP maximum packaging length for discrete double-stranded DNA fragments is 
between 1289 bp and 1737 bp. 
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Main theses of defence 
 Yeast-produced bacteriophage GA coat protein derived VLPs are capable to form mosaic 
particles, including HIV-Tat (48-60) sequence and immunologically competent region of 
WNV domain III. 
 Two-promoter system based on plasmid pESC-URA was used for in vivo packaging of IL-
2 and GFP mRNA into GA coat protein particles; the packaging specifity was remarkably 
improved by supplementing MS2 operator sequence to GFP mRNA and using GA VLP 
mutants that mimicks MS2 operator binding site, however particles still contained its own 
coat protein mRNA. 
 Mosaic particles containing phage AP205 coat protein and protein C-terminally fused with 
111 amino acids long WNV envelope protein E domain III sequence can be obtained in 
E.coli expression system. 
 Bacteriophage AP205 WNV DIII sequence containing mosaic VLPs elicit WNV specific 
antibody response after immunisation in mice. 
 Single-point mutations N75K, E77K, P79K and I80K in HBV core protein allow formation 
of particles morphologically indistinguishable from natural recombinat capsids. 
 Alkali treatment based technology can be used for depletion of HBV core VLPs inner 
content and obtain empty particles for bacterial, yeast and all four point-mutants HBc-75K, 
HBc-77K, HBc-79K and HBc-80K. 
 Empty HBc VLPs can package nucleic material either by direct contact incubation or 
through restoration in urea and refolding. 
 Empty HBc VLPs package, but remarkably degrade RNA material. 
 DNA material packaged in empty HBc VLPs is protected from DNAse I cleavage. 
 HBc VLP maximum packaging length for discrete double-stranded DNA fragments is 
between 1289 bp and 1737 bp. 
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Abstract 
Bacteriophage GA coat protein formed self-assembly competent virus like particles (VLPs) 
have been expressed previously in bacteria and yeast cells. On the base of our previous 
experiments in yeast vector pESC-URA / S.cerevisiae system containing two opposite oriented 
promoters, new constructions were created with point-mutations in coat protein to mimic phage 
MS2-like RNA binding characteristics. Simultaneously MS2 operator sequence was added to 
mRNA desired for packaging. After introduction of single-point mutations (S87N, K55N, 
R43K) and double-point mutations (S87N + K55N and S87N + R43K) coat protein ability to 
form VLPs was retained except that yield from cells was decreased. Exchange of the 87th Ser 
to Asn in coat protein sequence together in combination with bacteriophage MS2 translational 
operator provided specific packaging of the gene of interest (GFP). Although non-specific 
nucleic acid sequences were packaged, the remarkable specificity for packaging of the gene of 
interest using above mentioned approach can be achieved. 
Key words: VLPs, GA, MS2, operator 
 
Introduction 
Recent work is a further development of our previous investigations in the production of 
recombinant bacteriophage GA coat protein formed nanoparticles with in vivo packaged 
mRNAs. It was found that high-yield production of GA coat protein formed virus like particles 
(GA CP VLPs) occurred by expression of appropriate coding gene in yeast Pichia pastoris 
(Freivalds et al., 2008), whereas gene constructs based on vector pESC-URA from Stratagene 
in Saccharomyces cerevisiae gave much lower production of VLPs, which allowed to produce 
mosaic particles (Rūmnieks et al., 2008) and to pack mRNAs into particles during growth 
(Rūmnieks et al., 2008; Strods et al., 2013). 
It is well-known that the coat proteins of single-strand RNA bacteriophages are bifunctional. 
They form the icosahedral shells for protection of viral nucleic acids, and also shutting off viral 
replicase synthesis by binding to specific RNA hairpin that contains the replicase ribosome 
binding site. This hairpin structure is placed just downstream coat protein coding sequence, 
before the next- replicase coding sequence. The MS2 genome was the first genome to be 
completely sequenced by Walter Fiers and his team in 1976 (Fiers et al., 1976).  The above 
mentioned hairpin or stem-loop structure designated as a translational operator (Bernardi & 
Spahr, 1972) is also bifunctional. It is involved not only in the effective repressing of the 
synthesis of replicase, but also believed to be a packaging signal that initiates the assembly of 
the capsid and ensures recognition and selective encapsidation of the phage RNA. 
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Recombinant VLPs derived from bacteriophage coat proteins retains the ability for packaging 
of RNA (unspecific, host source). Nevertheless, translational operator sequences are involved 
into the target RNA sequences to improve specificity of packaging.  
RNA binding properties of the coat protein from bacteriophage GA was investigated by Dr. 
Uhlenbeck with co-workers (Gott et al., 1991). Filter binding assays in vitro showed that despite 
46 of 129 amino acid differences between GA (serological group II) and R17 (serological group 
I) coat proteins, the binding sites are fairly similar and GA coat protein binds RNA with 
„considerable specificity”. 
We have described previously that the operator had rather small effect on the specificity of 
capsid contents for recombinant capsids which are produced with and without GA-operator 
sequences in mRNAs (Strods et al., 2013). Therefore, many successful examples of use of MS2 
operator have been elaborated (Legendre & Fastrez, 2005; Pasloske et al., 1998; Pickett & 
Peabody, 1993; Wei et al., 2008). 
Altering RNA binding specificities of translational repressors and coat protein mutants that 
influence this binding were studied by Dr Peabody’s group (Lim et al., 1994; Lim & Peabody, 
1994). The first strategy of this study involves investigation of the affinity of the coat protein 
variants for RNA in vitro, and the second one includes measurements of translational repression 
in vivo. Taken together, the introduction of specific GA-like substitutions into MS2 coat protein 
sequence have been performed, which resulted in one case six amino acid substitutions 
(positions 43, 55, 59, 83, 87, 89) that markedly influenced the RNA binding sites of MS2 and 
GA coat proteins (Lim et al., 1994). In the next series the role of two additional substitutions 
(positions 29 and 66) and deletion of FG-loop was established (Lim & Peabody, 1994). Three 
of the most important mutations K43R, N55K and R83K were called by authors as „super-
repressor mutations”, because they bound both operator RNAs more tightly than wild type 
protein (Lim et al., 1994). The main determinant of the difference in GA and MS2 specificity 
seems to be the N87S substitution (Lim et al., 1994). Other codon-directed mutagenesis 
experiments confirmed earlier results showing that the identity of Asn-87 was for specific 
binding of MS2 RNA and for discrimination of Qb RNA binding (Spingola & Peabody, 1997). 
Intensively were studied also crystal structures of complexes between recombinant MS2 
capsids with mutations and RNA operator sequences (Helgstrand et al., 2002; Horn et al., 2004; 
Johansson et al., 1998; Valegârd et al., 1997). The conversion of Asn-87 to Ala improved the 
ability of purine-RNAs (GA operator type) to bind MS2 coat protein, but binding to pyrimidine-
RNAs (MS2 operator type) remained still to be more tight (Johansson et al., 1998). The authors 
also appointed the possible role of some other amino acids in the complex formation and 
particularly of Ser-52, Asn-55 and Lys-57. Lys-57 is present in all types of coat protein and 
therefore might not to be responsible for specificity of interaction. Instead of Ser-52 in GA is 
Gly, instead of Asn-55 in GA is Lys (Tars et al., 1997). It is assumed, that in spite of large 
differences in binding affinities, the structures of the variant complexes are very similar to the 
wild-type operator complexes, and the interaction of wild-type MS2 operator with native MS2 
coat protein seems to be if not the strongest one, but at least more functionally specific. Two 
new techniques based on wild-type MS2 protein-MS2 operator interaction have been developed 
recently. Those are MS2 tagging (Chubb et al., 2006) and tethering (Keryer-Bibens et al., 2008) 
techniques. MS2 tagging and tethering are based upon the high-specific interaction of the MS2 
bacteriophage coat protein with the stem-loop structure of the MS2 operator sequence. The 
mRNA packaging into VLPs in eukaryotes during growth process has one very distinguishing 
advantage – it goes through 3’-end- processing, which includes posttranslational cleavage of 
mRNA precursor with followed the 3’-end processing and polyadenilation (Colgan & Manley, 
1997; Dheur et al., 2005; Keller & Minvielle-Sebastia, 1997; Zhao et al., 1999), becoming 
functionally matured. Most eukaryotic mRNAs, with a very few exceptions, acquire a poly (A) 
tracts at their 3’-ends. Entity of the poly(A) tail in translation processes is the main importance 
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for mRNA function (Preiss & Hentze, 1999).  Poly(A) tail behaves as a stabilizing factor and 
in the absence or removal of its, mRNA is rapidly decapped and degraded. If we have plans to 
package functionally active mRNAs into virus like particles for delivery and „work” in a certain 
kind of eukaryotic cells, we must pack functionally active mRNAs, and the direct packaging in 
vivo during VLP growth solves this problem. It is known that in yeast poly(A) tails are with 
average length of about 70 adenosine residues, whereas in other (higher) mammals such tails 
are synthesized to an average length up to 250 adenosine residues (Dheur et al., 2005).  
For us was very important to combine our rather good results in production of GA CP VLPs 
with more specific packaging of desired mRNAs in vivo. Therefore, our goal was directly 
opposite to the Peabody’s work (Lim et al., 1994) – to introduce into GA coat protein such 
amino acids what would make them like MS2 coat protein (mimic them as MS2) for strong and 
specific interaction with MS2 operator sequence joined to packaged GFP mRNA. Single 
substitutions as well as combinations of these mutations in pairs (Table 1) were chosen. 
Simultaneously with this main task to improve packaging we must to find out under which 
promoter GAL1 or GAL10 it might get higher yield of VLPs and, basically, to fix the first cases 
for expression in yeast of the capsid formation facts from mutated GA coat protein. 
Several tasks were envisaged for this study. First of all to test the GA capsid formation by 
expression in yeast of GA coat protein with three single amino acid mutations (amino acids 43, 
55, 87) and with two double mutations (amino acids 43+87 or 55+87). Mutations for the 
introduction into GA coat protein sequence were chosen basing on the analysis of literature data 
(Gott et al., 1991; Lim et al., 1994; Lim & Peabody, 1994; Ni et al., 1996). It was also planned 
to compare the yield of VLPs dependency on construct – under which promoter was placed GA 
CP sequence. The next question for us was to analyse the amount of packaged RNA 
dependently upon obstacle mentioned above. And finally the last but not the least was to 
ascertain wherever the introduction of MS2 operator sequence into packaged GFP mRNA 
raised specificity of packaging also resulting in the best quality particles for further 
investigation. This final task was solved in the case of prognostic the more important mutation 
of 87th amino acid serine to asparagine. 
 
Materials and methods 
Plasmid constructions 
All constructions were based on plasmid pESC-URA (Agilent Technologies) for protein 
expression in yeast. This plasmid contains two promoters (GAL1 and GAL10) for expression 
of GA coat protein – unmodified and modified – and for synthesis of mRNA. New constructions 
are based on plasmids pIC921 and pIC984 (Strods et al., 2013) by introducing single amino 
acid change following standard site-directed mutagenesis protocol. PCR reaction mixture 
consisted from 2x PCR Master Mix (Thermo Scientific), pair of degenerate primers and 
template DNA as described in manufacturer’s protocol, and summarised in the Table 2 – 
constructions pIC994, pIC995, pIC989, pIC991, pIC996, pIC997 are based on either pIC921 
or pIC984 and constructions pIC904, pIC906, pIC905, pIC907 are based either on pIC994 or 
pIC995. In case of construction pIC1076, firstly, vector was obtained by digestion of plasmid 
pIC995 with restriction endonucleases EcoRI and NotI and, secondly, GFP sequence containing 
fragment from plasmid pIC921 was cloned out by using primers pINC-525 (5’-TCG AAT TCC 
ATG GTG AGC AAG GGC GAG GA-3’) and pINC-526 (5’-AAG CGG CCG CGA CAT 
GGG TAA TCC TCA TGT TTT GCT TAC TTG TAC AGC TCG TCC ATG CC-3’) and 
digested with abovementioned restriction endonucleases, and, thirdly, vector and fragment were 
ligated together. All constructs were produced through transformation in E.coli competent cells 
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and purification with GeneJET Plasmid Miniprep Kit (Thermo Scientific), followed by 
sequence verification using sequencing method. 
Expression of constructions 
Yeast Saccharomyces cerevisiae (S. cerevisiae) strain YPH499 (ura3-52 lys2-801amber ade2-
101ochre trp1-Δ63 his3-Δ200 leu2-Δ1, haplotype a) was transformed with all plasmid constructs 
according to the standard lithium acetate/polyethylene glycol procedure using Sigma-Aldrich 
Yeast Transformation Kit according to the protocol described by Gietz et al. (Gietz et al., 1992). 
Transformants were selected and grown in uracil-free synthetic dextrose minimal medium 
(SDU-) for maximum protein expression as described previously by Strods et al. (Strods et al., 
2013). 
Purification of VLPs 
Yeast cells were suspended in working buffer (20mM Tris-HCl, 5 mM EDTA, 0.65 M NaCl, 
pH7.8, supplemented with 0.03 mM PMSF) and subjected through French press (three strokes, 
20 000 psi), after which cell lysate was stirred with equal volume of glass beads (30 sec stirring 
and 1 min rest on ice, repeated 15 times) and sonicated at 22 kHz (14 sec sonicate and 1 min 
rest on ice, repeated 15 times). Cell lysate was centrifuged (30 min at 12 000 rpm), debris was 
additionally washed with working buffer and volume of joined supernatants was reduced by 
dialysis against solution consisting from mixture of working buffer and glycerol (1:1 by 
volume). Afterwards, VLPs were subsequently purified through Sepharose CL-4B gelfiltration 
column (2 x 63 cm), eluting them with working buffer (at flow rate 2 ml per hour). As a next 
step was purification through DEAE Sephadex A-50 column (1 x 5 cm) – samples were 
subjected on column, then flow-through and additional washing with 3 ml of TEN buffer 
(20mM Tris-HCl, 5 mM EDTA, 0.15 M NaCl, pH7.8) were combined in dialysis tube and 
concentrated using dry Sephadex G-100 powder (GE Healthcare). 
Products were purified by sucrose density gradient centrifugation, using preformed stepwise 
sucrose gradient from 36% till 5% sucrose concentration in working buffer (total volume of 
each tube - 12 ml, centrifugation was performed at 25000 rpm for 13h in Beckman Coulter 
Optima L-100XP ultracentrifuge (rotor SW32 Ti)). After piercing the bottom of the tube, 
fractions were collected (1 ml each) and those containing VLPs were joined together, dialysed 
against working buffer and, if necessary, concentrated using dry Sephadex G-100 powder. 
VLPs preparations from constructions IC991, IC989, IC995 and IC996 were subjected onto the 
two equal layer CsCl gradient, where the bottom 6 millilitre was from ready solution (44 g CsCl 
+ 60 ml working buffer), and the upper 6 millilitre consisted of VLPs solution, 2.2 g of CsCl 
and working buffer. Ultracentrifugation and fractionation were performed similarly as with 
sucrose gradient, with only the exception that 20500 rpm for 13h regime was used. 
Extraction of VLPs inner content 
To the solution of VLPs the mixture of equal amounts of phenol and chloroform (1:1) was 
added, thoroughly vortexed and centrifuged (8000 rpm for 5 min). Upper (aqueous) phase was 
subtracted, washed triple with diethyl ether and nucleic acids were precipitated by adding 
ethanol. After centrifugation (13000 rpm for 15 min), the debris was washed with 70% ethanol 
and dissolved in DEPC-water. RNA quantity measurements were carried out using ND-1000 
spectrophotometer (NanoDrop). 
Purification of poly-A tail containing RNA 
In order to measure mRNA content in whole RNA extract from VLPs, affinity chromatography 
using oligo(dT)-cellulose (Sigma-Aldrich) column was used. Oligo(dT) cellulose was 
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incubated with RNA in binding buffer (10mM Tris-HCl, 1mM EDTA, 400mM NaCl, 0.1% 
SDS) at 65°C 10 min, followed by washing with binding buffer, washing buffer (10 mM Tris-
HCl, 1 mM EDTA, 100 mM NaCl, 0.1% SDS) and finally eluted with elution buffer (10 mM 
Tris-HCl, 1 mM EDTA, 0.1% SDS). mRNA containing elution fractions were combined and 
total amount of RNA was determined using optical density measurements. 
Reverse transcription qPCR 
Reverse transcription real-time PCR (RT-qPCR) was done in two steps. Firstly, cDNA with 
random hexamer or oligo(dT) primers were synthesized from equal amount of each sample by 
using First Strand cDNA Synthesis Kit (Thermo Scientific) according manufacturer’s 
recommendations, using from VLPs extracted total RNA as a template. Secondly, qPCR 
reaction mixture for each sample was prepared in duplicates as follows – 6 µl Power SYBR 
Green PCR Master Mix (Life Technologies), 2 µl H2O, 2 µl primer mix (2pmol/µl), 2 µl cDNA 
(diluted two-fold). qPCR reaction was done on ViiA™ 7 Real-Time PCR System (Life 
Technologies) according pre-set protocol for SYBR Green qPCR reaction. Ct values were used 
to calculate 2deltaCt to represent the amount of PCR product. 
 
Results 
Synthesis and purification of virus-like particles 
For all constructions from pIC904 till pIC1067 (listed in Table 1) were used plasmids pIC921 
and pIC984, based on commercial plasmid pESC-URA (Stratagene) and contained 
bacteriophage GA coat protein sequence with optimized codons that was described previously 
(Strods et al., 2013). In synthesis process (described in Methods and Table 2) totally were 
generated 11 constructions which included single-point mutations S87N, K55N, R43K and 
double-point mutations S87N + K55N and S87N + R43K. In Figure 1 is shown construction of 
main interest – IC1067 – based on IC984 and containing bacteriophage MS2 operator sequence 
added to the 3’ end of the GFP gene in order to provide more specific packaging of GFP gene 
through binding of operator’s stem-loop structure (Figure 2) with modified bacteriophage GA 
coat protein. After transformation and protein expression in yeast S. cerevisiae all of the above 
mentioned constructions (with exception of construction IC997) produced virus-like particles. 
A typical example of purification process is shown in the case of IC984 VLPs (Figure 3), where 
fractions after cell lysate gelfiltration on Sepharose CL-4B column were measured in 
spectrophotometer (Figure 3A) and analysed on agarose gel electrophoresis (Figure 3B). 
Presence of nucleic acid seen in fractions with VLPs (agarose gel) promoted us to introduce 
purification on DEAE ion-exchange column. Due to the overall positive charge of GA VLPs, 
they were eluted from column as unbound material free from nucleic acid contamination. As a 
last step, additional purification using sucrose density gradient ultracentrifugation was done 
(Figure 3C). Similarly were purified IC989 VLPs, using other Sephadex CL-4B column (Figure 
4A), Coomassie stained PAGE (Figure 4B) and Western blot (Figure 4C) analysis methods 
were used to reveal fractions that contain coat protein. In similar manner VLPs from all 
constructions were obtained, then the yield was calculated and summarized in the Table 3. The 
presence of VLPs was confirmed via electron microscopy, showing two variants as an example 
(Figure 6). 
As it can be seen in the Table 3, the best yield after VLPs purification is observed in case of 
constructions where no modification in coat protein are inserted, respectively, in constructions 
IC921 and IC984, and these data roughly correspond to the yield of the VLPs, formed from GA 
coat protein, expressed from native coat protein sequence (Freivalds et al., 2008). At the same 
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time the yield was lower than in the case of construction A65 [3] that can be probably explained 
with additional stress for the yeast cells to transcribe and synthesize both coat protein and GFP 
gene. Comparing gene placements under promoters, the yield of the VLPs differed almost twice 
in favour for the coat protein placed under GAL1 promoter (i.e., construction IC984). 
All other constructions bearing point-mutations in coat protein amino acid sequences show 
noticeably lower yields of VLPs per gram of cells. Yields of VLPs according to the placement 
of the coat protein under GAL1 or GAL10 promoter were different and showed no obvious 
regularity. Also no coherences between VLPs yields and different mutations – either single or 
double amino acid exchanges – were found, suggesting that our mutations introduced in 
different places of the coat protein sequence did not significantly interfere the protein 
production or particle assembly process. Exception in this series showed only one construction 
– IC1067, with mutation (S87N) in coat protein and MS2 operator sequence added to the 
GFP sequence. Appropriate construction without MS2 operator sequence (IC995) showed 
almost four times less yield of VLPs, indicating important role of MS2 operator in process of 
particle formation. 
Analysis of VLPs inner content 
Comparing VLPs yield and RNA yield from purified VLPs (Table 3), direct correlation can be 
seen, possibly suggesting important role of RNA packaging ability and assembly of VLPs. 
Lowest RNA packaging capacity can be seen in construction IC904 and IC906 bearing S87N 
and K55N double-mutation, but otherwise – no prevalence of RNA packaging level in 
comparison with the location of the coat protein under GAL1 or GAL10 promoter. 
Constructions that each possess different point-mutation were compared in CsCl density 
gradient (Figure 5), and also this method revealed divergent properties of those VLPs. VLPs 
with mutations S87N (IC995) and R43K (IC996) showed similar densities, but mutation K55N 
(constructions IC991 and IC989) bearing VLPs showed markedly lower density of VLPs in 
CsCl density gradient. These disparities in VLPs densities can explain also different yield and 
inner filling of the VLPs. 
No prevalence of mRNA packaging in the case of construction IC1067 was observed. Despite 
the varieties of the mRNA content in different constructions, its average amount roughly 
corresponds to the relative amount of mRNA from total RNA found in yeast cells (Table 3). 
Total RNA from two constructions – constructions IC984 containing GFP gene and 
construction IC1067 containing GFP gene supplemented with MS2 operator – were used as a 
template for quantitative PCR. cDNA from total RNA pool and mRNA pool were obtained 
using random hexamer and oligo(dT) primers, respectively. Despite the fact that extracted RNA 
does not contain any reference genes, we assumed that real time PCR data are comparable due 
to the fact that initial RNA was taken in equal amounts between both samples (Figure 8). Real 
time PCR analysis with GFP primer set revealed the presence of GFP gene in both VLPs, 
however when GFP gene was prolonged with MS2 operator sequence (IC1067), the packaging 
level in S87N coat protein mutant VLPs was at least one and a half higher (Figure 8, random 
hexamer cDNA with GFP primers). Analysing packaging level of the GFP specific mRNA, we 
can see difference even more – at least three times (Figure 8, oligo(dT) cDNA with GFP 
primers). Using MS2 operator specific primer set, the prolongation of GFP mRNA sequence 
with MS2 operator sequence was confirmed (Figure 8, MS2 operator primers). 
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Discussion 
Exploration of above mentioned construction are meant to cover different things – possibility 
to form VLPs, the yield of VLPs and its dependency from coat protein placement under one of 
the two promoters, the RNA filling level and also the specificity of its packaging. Formation of 
VLPs were observed in all except one construction therefore it was possible to investigate other 
abovementioned statements. Our previous observations in the case of VLPs with unmodified 
coat protein showed overall better VLPs yield in comparison with mutant constructions. While 
in all mutation containing constructions yields of the VLPs were lower independently from 
promoters. Our idea of duplicate constructs with opposite orientation of genes (regarding 
placement under GAL1 or GAL10 promoter) was to find best combination for increasing of 
VLPs production and for ensuring specific packaging. Minor variations of VLPs yield in mutant 
constructs were observed, but no clear preference in favour to coat protein alignment under one 
of the promoters was discerned. The same was observed when total RNA was extracted and 
also mRNA purified, suggesting that gene placement under promoter influence VLPs yield and 
inner content, but it is not the only factor and for the optimal results different construction 
strategies should be used. When comparing VLPs yield and total RNA amount among all 
constructions, direct correlation can be seen allowing for us to hypothesize that wholesome 
nucleic acid filling is necessary for optimal self-assembly of the capsids. 
Observed higher yield of VLPs due to the coat protein placement under GAL1 promoter in 
S87N mutant encouraged us to add MS2 operator exactly to this construction. As a result was 
created construction of our interest - IC1067, which was examined in more details. Introduction 
of the point mutation S87N in GA coat protein resulted in more specific interaction with the 
MS2 operator sequence, especially in the comparison with the GA operator interaction with GA 
coat protein (Rūmnieks et al., 2008). Packaging of the mRNA of interest (in our case – from 
GFP gene supplemented with MS2 operator) was also higher, proving our hypothesis that 
specific attachment of the MS2 operator sequence to the modified coat protein can provide 
specific packaging of RNA. These results are in the accordance with Lim’s et al. (Lim et al., 
1994), that the main determinant for the specificity of MS2 operator binding is S87N 
substitution in coat protein. More specific packaging of RNA is also strong enough to partially 
compensate negative effects of amino acid exchange in coat protein, therefore rising overall 
VLPs production level. Nevertheless that the positive tendency for specific packaging is 
realised, VLPs still contains a broad spectra of internal filling. Sample analysis with coat protein 
specific primers showed that full specificity of GFP packaging was not achieved and VLPs 
contained significant amount of coat protein gene mRNA (Figure 8). Some previous packaging 
experiments on the basis of the GA operator indicated the same tendency, that even some 
specificity of the gene of interest was achieved, full exclusion of unnecessary amino acid 
sequences could not be done (Rūmnieks et al., 2008). Mimicking of GA virus like particles 
toward MS2 like particles gave relatively more specific packaging of the sequence of interest – 
it was found that GFP mRNA with MS2 operator (Figure 8, oligo(dT) cDNA with GFP primers) 
was packaged approximately three times better than without operator. 
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Tables 
Table 1. Constructions for expression of GA CP and/or GFP in yeasts. 
Introduced 
mutation(s) 
Construct 
Nr 
Construct 
GAL1 GAL10 
921 GFP GA CP 
984 GA CP GFP 
S87N 
994 GFP GA CP (S87N) 
995 GA CP (S87N) GFP 
1067 GA CP (S87N) GFP + MS2op 
K55N 
989 GFP GA CP (K55N) 
991 GA CP (K55N) GFP 
R43K 
996 GFP GA CP (R43K) 
997 GA CP (R43K) GFP 
S87N; 
K55N 
904 GFP 
GA CP (S87N; 
K55N) 
906 
GA CP (S87N; 
K55N) 
GFP 
S87N; 
R43K 
905 GFP 
GA CP (S87N; 
R43K) 
907 
GA CP (S87N; 
R43K) 
GFP 
 
 
Table 2. Summary of constructions made with site-directed mutagenesis method. 
Construct primers template 
DNA 
pIC994 pINC-439 (5’-TGG AAG GCA TAT GCT AAT ATT 
GAT TTG AC-3’) and pINC-440 (5’-GTC AAA TCA 
ATA TTA GCA TAT GCC TTC CA-3’) 
pIC921 
pIC995 pINC-439 and pINC-440 pIC984 
pIC989 pINC-437 (5’-GCT TCT GGT GCT GAT AAT AGA 
AAA TAT AC-3) and pINC-438 (5’-GTA TAT TTT 
CTA TTA TCA GCA CCA GAA GC-3) 
pIC921 
pIC991 pINC-437 and pINC-438 pIC984 
pIC996 pINC-451 (5’-CAA GCA TAT AAA GTT ACT GCT 
TC-3’) and pINC-452 (5’-GAA GCA GTA ACT TTA 
TAT GCT TG-3’) 
pIC921 
pIC997 pINC-451 and pINC-452 pIC984 
pIC904 pINC-437 and pINC-438 pIC994 
pIC906 pINC-437 and pINC-438 pIC995 
pIC905 pINC-451 and pINC-452 pIC994 
pIC907 pINC-451 and pINC-452 pIC995 
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Table 3. Yield of purified VLPs per g of cells and yield of total RNA and mRNA extracted 
from purified VLPs. 
 
Nr 
Construction yield, mg 
VLPs per 
gram cells 
µg of RNA from 
1 mg of VLPs 
% of 
mRNA 
from 
total 
RNA 
GAL1 GAL10 
total 
RNA 
mRNA 
IC921 GFP GA CP 0.872 104.2 8.6 8.3% 
IC984 GA CP GFP 1.525 168.6 29.8 17.7% 
S
8
7

N
 
IC994 GFP 
GA CP 
(S87N) 
0.184 32.4 2.4 7.4% 
IC995 
GA CP 
(S87N) 
GFP 0.271 42.0 4.2 10.0% 
IC1067 
GA CP 
(S87N) 
GFP + 
MS2op 
0.943 104.4 14.0 13.4% 
K
5
5

N
 
IC989 GFP 
GA CP 
(K55N) 
0.312 56.2 12.6 22.4% 
IC991 
GA CP 
(K55N) 
GFP 0.183 38.2 2.4 6.3% 
R
4
3

K
 
IC996 GFP 
GA CP 
(R43K) 
0.110 30.4 2.2 7.2% 
IC997 
GA CP 
(R43K) 
GFP -  165.2 0.0 - 
S
8
7

N
; 
K
5
5

N
 IC904 GFP 
GA CP 
(S87N; 
K55N) 
0.163 16.2 2.0 12.3% 
IC906 
GA CP 
(S87N; 
K55N) 
GFP 0.240 12.4 2.6 21.0% 
S
8
7

N
; 
R
4
3

K
 IC905 GFP 
GA CP 
(S87N; 
R43K) 
0.250 24.2 2.2 9.1% 
IC907 
GA CP 
(S87N; 
R43K) 
GFP 0.233 52.0 2.6 5.0% 
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Figures 
Figure 1 Plasmid map for construction 1067 (created with Vector NTI software package 
(Invitrogen)). 
 
 
 
Figure 2 Secondary structure of MS2 RNA operator stem-loop, compared with GA RNA 
operator stem-loop (according Lim et al. 1994 (Lim et al., 1994)). 
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Figure 3 Purification steps of IC984 VLPs: optical density (A) and native agarose gel 
electrophoresis (B) profile after column chromatography on Sephadex CL-4B; (C) optical 
density profile of sucrose gradient (fraction size 0.5 ml). Brackets show collected fractions, in 
agarose gel electrophoresis red ellipse and blue ellipse show VLPs and nucleic acids, 
respectively. 
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Figure 4 Purification steps of IC989 VLPs: optical density (A), native agarose gel 
electrophoresis (B) and Western blot (C) profile after column chromatography on Sepharose 
CL-4B. Red arrow points to the coat protein monomer. 
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Figure 5 Optical density profiles of sucrose density gradients for IC991 (A), IC995 (B), IC996 
(C) and IC989 (D) VLPs. Brackets show collected fractions. 
 
 
 
Figure 6 Electron microscopy images with purified IC995 (A) and IC996 (B) VLPs. 
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Figure 7 Oligo(dT) cellulose affinity chromatography of the RNA, extracted from construction 
IC984 and analysed in a denaturing 1% FA agarose gel. Samples are as follows: M - RiboRuler 
High Range RNA Ladder; 1. – total extracted RNA from VLPs; 2. – washing buffer fraction 
from oligo(dT) column; 3. – eluted mRNA from oligo(dT) column. 
 
 
 
Figure 8 Real-time qPCR, using appropriate (gene specific) primers and cDNA amplified with 
random hexamer or oligo(dT) primers from extracted VLPs RNA as a template. Graphs are 
showing 2deltaCt values. 
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In vivo iepakošana raugos producētās no bakteriofāga GA atvasinātās vīrusiem-līdzīgās 
daļiņās 
Bakteriofāga GA apvalka proteīna veidotās pašsavākties spējīgās vīrusiem-līdzīgās daļiņas 
(VLD) ir ekspresētas baktērijās un raugos. Uz iepriekšējo eksperimentu bāzes divus pretēji 
vērstus promoterus saturošā rauga vektora pESC-URA / S.cerevisiae sistēmā tika izveidotas 
jaunas konstrukcijas ar punktveida mutācijām apvalka proteīna gēnā, lai iegūtu MS2 fāgam 
līdzīgu RNS saistību. Vienlaicīgi pie iepakojamā mRNS tika pievienota MS2 operatora 
sekvence. Pēc punktveida (S87N, K55N, R43K) un dubultmutācijām (S87N + K55N and S87N 
+ R43K) apvalka proteīns saglabāja spēju veidot VLD, lai arī ar mazāku iznākumu no šūnām. 
Serīna nomaiņa uz asparagīnu 87. apvalka proteīna sekvences pozīcijā kombinācijā ar 
bakteriofāga MS2 translācijas operatoru nodrošināja interesējošā gēna (GFP) specifisku 
iepakošanos. Lai arī tika iepakotas nespecifiskas nukleīnskābju sekvences, ievērojama 
interesējošā gēna specifiska iepakošanās var tikt panākta izmantojot iepriekšminēto pieeju. 
 
